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General Introduction and Objective of the Thesis
4Chapter 1
Tuberculosis (TB) is a communicable disease caused by Mycobacterum tuberculosis, which occurs 
worldwide with a high burden in the developing countries. Successful treatment has been reported 
for decades and cumulative knowledge about this disease is available nowadays. Still, even in the early 
21st century TB remains a high-burden infectious disease with high morbidity and mortality. One-third 
of the world population is infected with Mycobacterium tuberculosis in its dormant state. About 9 
million of those infected develop the disease, and this number increases annually (1). This brings up 
questions as to whether our current strategy to control this disease is the best one. It is not easy to find 
answers but two subjects need to be addressed in the fight against TB. First, TB is easily transmitted in 
the community, which challenges our effort to prevent its spreading. TB is often detected late, result-
ing in late confirmation of the right diagnosis. This increases the risk of infecting many other individuals 
in the community (2). Failure to recognize the infection in time results in late initiation of treatment 
or no treatment at all. Second, TB treatment faces many difficulties, the most worrisome of which 
are multi-drug resistance/extensively drug resistance (MDR/XDR) TB and the combination of TB-HIV. 
Drug-drug interactions and high risk of toxicity resulting in non-adherence complete the challenge of 
treatment optimization. 
TuberCulosis ConTrol in PrivaTe PharmaCies
In the developing world, TB control is challenged by many problems. The lack of health care facilities 
and human resources prevent the National Tuberculosis Program (NTP) from establishing a compre-
hensive system for this purpose. Vietnam is one of the countries to have successfully established a 
TB control system with a high political commitment that covers the whole country, including remote 
areas (3). Vietnam achieved the target of the World Health Organization for TB diagnosis and suc-
cessful treatment for about 10 consecutive years, yet the notification rate did not decrease as desired 
(3-5). The potential reason is that substantial proportions of patients were diagnosed late or were not 
detected at all. This resulted in the transmittance of M. tuberculosis to other people even before diag-
nosis. TB patients in Vietnam, like most low- and middle-income countries, were treated not only in 
the public sector as NTP but also in the private sector. Previous data suggests that private pharmacies 
are most likely the source causing the delay in diagnosis and the ensuing treatment (4,5). No clear 
explanation has been found as to why this factor is the main cause of diagnostic delay to date. Phar-
macists who are in charge of private pharmacies may provide the answer for this question. So far, the 
private sector is still out of NTP’s understanding and efforts have been made to establish collaboration 
between the two sectors in the form of a public-private mix (6). Incorporating private pharmacies into 
this program proved to be a successful approach to increase case detection (7). Therefore, the aim of 
this thesis was to explore the role of private pharmacies in tuberculosis control in a complex setting 
(Hanoi) of a developing country (Vietnam). 
TuberCulosis TreaTmenT oPTimizaTion
To date, TB treatment follows standardized dosing. The main idea behind this is to reach efficacy 
in a majority proportion of patients with a minimum of toxicity. This approach is an economic and 
easy way to achieve successful treatment outcome in the general patient population (1,8). However, 
in daily practice physicians and clinical pharmacists handle individual patients and not all of them fit 
this approach. For those patients, individualized treatment by means of therapeutic drug monitoring 
(TDM) is highly recommended to ensure enough exposure for adequate efficacy and to avoid toxicity 
(9-16). Studies based on in vitro models and clinical data on anti-TB drugs suggest that inter-patient 
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variability plays an important role in the emergence of resistance and failure (17-19). Assessing drug 
concentration by means of TDM could help assure adequate drug exposure while reducing the risk of 
toxicity. TDM may have the additional benefit of helping physicians cope with disease-drug interac-
tion, drug-drug interaction and non-adherence. Implementing traditional plasma sampling for TDM 
faces many hurdles, like lack of sample stability and the need for venipuncture to collect the sample. 
This may be one reason why TDM has not yet been implemented in NTP. A new applied procedure in 
the field of pharmacokinetics is dried blood spot (DBS) sampling, which has been used to screen meta-
bolic diseases among infants for decades (20). A dried blood spot (DBS) is obtained from blood by a 
finger prick, then put on an absorbing paper. With the advantage of high stability, lower blood volume, 
easy sampling and lower biohazard risk, DBS is an attractive alternative specimen that can make TDM 
possible, even in a resource-limited area (21). DBS has already been applied in the sampling procedure 
for many drugs such as immunosuppressants, antiretroviral agents and antimalarial drugs. Peculiarly, 
available data on DBS for anti-TB drugs are scarce (22).  Therefore, the aim of this thesis was to develop 
bioanalytical methods that are useful for TDM of anti-TB drugs using DBS sampling. In addition, the 
requirements, obstacles and solutions for developing and applying dried blood spot method for TB 
drugs were assessed. 
objeCTive of The Thesis
To summarize, the objectives of this thesis were to explore the role of private pharmacies and to 
develop and evaluate DBS sampling for anti-TB drugs both as potential new additives for improving TB 
control and treatment outcome.
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absTraCT
settings: Private Pharmacies in hanoi, vietnam.
objectives:  To explore the response of healthcare providers (hCPs) in private pharmacies 
to suspected tuberculosis patients.
methods:  a simulated patient method combined with an interview in 128 randomly 
selected private pharmacies and 10 private pharmacies nearby the tuberculo-
sis hospitals.
results:  fifty nine (46%) and 70 (55%) of hCPs referred the suspected tuberculosis to 
general healthcare in the simulated patient method and interview, respec-
tively. only 11 (9%) referred the simulated tuberculosis patient to a tubercu-
losis care facility. fifty-two (42%) of the hCPs identified tuberculosis from a 
fictitious case described on paper; 34 (27%) were aware of the free treatment 
in the national Tuberculosis Program (nTP). awareness of the free treatment 
in the nTP predicted a higher rate of direct referral to tuberculosis facilities 
(or=5.80, 95%Ci=1.88-19.62) and better ability to detect tuberculosis from 
a paper fictitious case (or=5.14, 95%Ci=2.36-11.73). Pharmacies certified as 
Good Pharmacy Practice (GPP) were less likely to refer simulated patients 
to tuberculosis facilities than non-GPP pharmacies (or=0.10, 95%Ci=≤0.01-
0.79).
Conclusions:  nearly half of hCPs in private pharmacies do not refer suspected tuberculo-
sis patients, possibly contributing to the delay in diagnosis and treatment. 
awareness of the nTP’s free treatment predicted better performance of 
hCPs.
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inTroDuCTion
Tuberculosis (TB) is a communicable disease occurring worldwide, 55% of global  cases are notified in 
Asia. Vietnam is a high burden country, with an incidence of 150 000 TB patients per year (1). To reduce 
the burden of TB and associated morbidity and mortality, the World Health Organization (WHO) rec-
ommends the DOTS stategy . This strategy, emphasising case detection and standardised treatment 
both free of charge, was successfully implemented in Vietnam by the National TB Control Programme 
(NTP) (2,3). Hanoi is the second biggest city in Viet Nam, with population of approximately 3 million 
and an estimated TB prevalence of 146 per 100 000 population (3,4). TB cases are diagnosed using 
sputum smear examination and/or chest X-ray and, in some cases, sputum culture. Most facilities 
designated for TB diagnosis were established inside the NTP system; this includes the central TB hos-
pital (the National Hospital for Lung Diseases) provincial TB hospitals/units and district TB units (3,4).
Private pharmacies constitute an important part of the private healthcare sector in many low- and 
middle-income countries (5,6). It is well known that private pharmacies also play a substantial role in 
diagnosis and treatment of TB (7-11).  However, the link between  private pharmacies and the public 
sector in TB control is still underdeveloped (3,12-14). Several studies have showned that in Vietnam pri-
vate pharmacies were the most important cause of delays in diagnosing TBand, initiating TB treatment 
(15,16). Proposed causes are prescriptions by private pharmacies for suspected TB patients instead of 
referrals to designated health facilities for diagnosis. (9,11). However, it is not clear whether private 
pharmacies are unable to identify TB suspects or unwilling to refer them. Furthermore, factors that 
affect the performance of health care providers (HCPs) in private pharmacies are unknown. To explore 
the referral behaviour of HCPs towards TB suspects, we performed a study using a simulated  patient 
method and interview in private pharmacies in Hanoi. 
PoPulaTion anD meThoDs
setting and sample
A list of all 1308 private pharmacies registered in nine urban districts of Hanoi was provided by the 
respective District Health Bureaux. We aimed to achieve a 95% confi dence interval (95%CI) of ±0.08 
for an estimated proportion of 0.5; the required sample size was therefore 135. A pilot survey of 20 
pharmacies from this list revealed that half of the pharmacies could not be found at the address pro-
vided, and that of those found 70% (7/10) agreed to participate. To correct for these expected losses, 
380 pharmacies were randomly selected from the list. The in-depth interview in the pilot study sug-
gested that pharmacies located near the two TB hospitals in Hanoi (the National Hospital for Lung 
Diseases and Hanoi Tuberculosis and Lung Disease Hospital) may have different TB control activities. 
An additional sample including all pharmacies within 500 m of the two TB hospitals was therefore 
selected as a subgroup.
By 2010, private pharmacies in Hanoi were being upgraded and given Good Pharmacy Practice (GPP) 
certification due to changes in policy of the Ministry of Health. The GPP certificate was granted accord-
ing to standardized criteria related to regulations, infrastructure, personnel and education; however, 
none of these focused on TB control. As the upgrading was still in progress at the time of this survey, 
both GPP and non-GPP pharmacies existed All HCPs from the selected pharmacies were asked to take 
part in a study on ‘respiratory diseases’. They were informed that the study consisted of two parts that 
would be audio recorded: a visit by a simulated patient and an interview. Signed informed consent was 
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obtained for all participating HCPs. The study was approved by the Ethical Review Board of the Hanoi 
University of Pharmacy.
Design
The pharmacies first received a visit from a simulated patient, followed by an interview 1 week to 2 
months later. The simulated patient method and interview were conducted by 10 trained research 
assistants (4 men and 6 women, age 23–26 years), who were students or lecturers from the Hanoi 
University of Pharmacy. The research assistant group was trained in 3 days to improve their knowledge 
of TB and interviewing skills, and participated in a role-playing workshop on the simulated patient 
method. For each pharmacy, the simulated patient and the interviewer were different to avoid pos-
sible bias during the case detection phase of the interview section. As pharmacies could have more 
than one HCP, the two research assistants ensured that the same HCP participated in both parts of the 
study. 
The simulated patient method: 
The simulated patient claimed to be suffering from cough and fever for 4 weeks. No improvement had 
occurred after two 10-day courses of antibiotics (amoxicillin followed by spiramycin). Furthermore, the 
simulated patient had been in contact with a TB patient and suggested that he/she might have con-
tracted TB. Anti-tuberculosis drugs were requested. If additional questions were asked, the symptoms 
of mild fever, productive cough and no clear improvement with cough suppressants were mentioned. 
The ‘patient’ wrote down the decisions of the HCP and the drugs dispensed immediately after leaving 
the pharmacy.
The interview: 
A structured questionnaire was developed using the adjustments from the pilot study. The interview 
consisted of general questions about the HCP and the characteristics of the pharmacy, followed by 
questions about a fictitious case on paper and knowledge about the NTP. 
Fictitious case on paper: 
A 50-year old man had been suffering from cough and fever for 4 weeks, for which he had taken a 10-day 
course of oral spiramycin with no improvement He visits your pharmacy and asks for your advice.
Q1: What would you do for this case? 
If the HCP wanted to know more about the case, he/ she was informed that the patient suffered from 
mild fever, productive cough and had experienced no clear improvement using cough suppressants. 
Q2: What disease/diseases do you think this patient is suffering from?
Knowledge about the National TB Control Programme
Q3: Are you aware of the NTP?
Q4: What are the costs of anti-tuberculosis drugs provided by the NTP?
Chapter 2
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The responses of the HCPs were noted immediately. The study design (simulated patient method fol-
lowed by interview) is briefly presented in the Figure
Data collection, revision and analysis
Data collection forms were cross-reviewed by another research assistant with the help of the audio-
tapes, which were also used to ensure that for each pharmacy only one HCP participated in the study. 
All data collection forms were double-checked by a researcher and translated into English. A Microsoft 
Access 2007 (Microsoft Corp, Seattle, WA, USA) database was made, after which data analysis was 
performed in R 2.10.1 (GNU Project, Vienna, Austria, www.r- project.org).
To explore determinants for referral and the ability to identify TB cases by the HCPs, Firth’s penal-
ized logistic regression was performed using a stepwise approach (17).  Categorical variables used in 
this analysis were transformed to dichotomous variables. The backward stepwise approach was per-
formed as  follows: the determination of potential covariates using univariate analysis with a cut-off P 
value of 0.2, building multivariate models consisting of potential covariates, and finally, the removal 
in succession of variables with no significant (P > 0.05) or confounding effect (changes in odds ratios 
[ORs] of the remaining variables of <15%).
resulTs
Of the list of 1308 pharmacies, 380 were randomly selected; 206 were found (54%), of which 129 (63%) 
agreed to participate in the study. One record was lost due to technical problems. Data from 128 phar-
macies were thus analysed as the main group. Among 20 pharmacies located close to the TB hospitals, 
three were already selected for the main group and seven refused to participate, leaving a subgroup of 
10 (50% of 20) pharmacies. A total of 138 pharmacies were included in the study.
GPP certification was obtained by 30 (23%) pharmacies in the main group. Most participating HCPs 
were assistant pharmacists who had received 2 years’ training (67%), 17% were drug sellers who had 
received 6 months’ training and 9% were pharmacists who had completed a 5-year pharmacy pro-
gramme at the university level. Medians (interquartile ranges) of the HCPs’ age and working experi-
ence in the pharmacies were respectively 26 (23–37) and 4 (2– 10) years. A similar pattern was observed 
in the subgroup (Table 1). 
When confronted by the simulated patient, 68 (53%) HCPs decided to dispense drugs, none of which 
were anti-tuberculosis drugs; 59 (46%) HCPs referred the patient for diagnosis: of these, 48 (38%) 
referred the patient to general health care and 11 (9%) to a designated TB facility. Responses to the ficti-
tious case on paper by 58 (45%) HCPs were to sell drugs and by 70 (55%) HCPs to refer to health care 
services.. Drugs suggested by the HCPs for the fictitious patient on paper did not include anti-tuber-
culosis agents.  The diseases most frequently mentioned were pneumonia (45%), TB (40%) and bron-
chitis (39%). HCPs mentioned TB as a possible disease and were considered to be able to identify TB 
from the fictitious case on paper. One hundred and three (80%) respondents said that they were aware 
of the NTP; of these, 34 (27%) knew that anti-tuberculosis treatment by the NTP was free of charge. In 
general, the subgroup had the same results as the main group (Table 2).The two outcomes of interest 
were referrals in the simulated patient method and the ability to identify suspected TB from the ficti-
tious case on paper. The potential covariates of referring TB suspects to a TB hospital in the univariate 
analysis were sex, GPP certification and knowing that NTP treatment was free of charge. However, sex 
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did not show a significant correlation in the multivariate analysis. Work experience, being an assistant 
pharmacist and awareness about free NTP treatment were potential covariates for the detection of 
TB in the fictitious case in the univariate analysis, while only awareness about free treatment was a 
significant predictor in the multivariate analysis. Simulated patients had a higher probability of being 
referred directly to a TB facility if the HCP was aware about free NTP treatment (OR 5.80, 95%CI 1.88–
19.62). Knowledge about free NTP treatment was also a predictor of the ability of HCPs to identify TB 
in the fictitious case (OR 5.14, 95%CI 2.36–11.73). GPP-certified pharmacies were less likely to refer the 
simulated patient to a TB facility than non-GPP pharmacies (OR 0.10, 95%CI ⩽0.01–0.79) (Table 3).
DisCussions
Our study showed that about more than half of the HCPs were willing to dispense drugs either for 
the simulated patients or the fictitious case on paper. The drugs tentatively dispensed were mainly 
antibiotics, anti-inflammatory or anti-allergic agents and cough suppressants. Although 49% of the 
private pharmacies stored at least two first-line anti- tuberculosis drugs (data not shown), no anti- 
tuberculosis drugs were dispensed by self-prescription even when the simulated patient mentioned 
that he/she could have TB and asked for TB medication. The caution on the part of the private pharma-
cies in our study differed from the results from previous surveys in Ho Chi Minh City, where >20% of 
pharmacies were willing to dispense TB drugs without prescription (9,11). To some extent, this fiding 
reflects the success of the health authorities and the NTP in controlling indiscriminate dispensing of 
anti-tuberculosis drugs by private pharmacies. Nonetheless, the willingness to dispense non-TB drugs 
could increase the delay in TB diagnosis if the suspected patient was a real TB patient, and may explain 
why private pharmacies were potential sources of TB diagnostic delay in previous studies (15,16). Fur-
thermore, patients who were referred to a general health facility could also be at risk of diagnostic 
delay, as the general health care services have also been reported to contribute to delay (15,16,18). 
Only approximately 10% of HCPs referred the simulated patient to the designated TB facility where 
diagnosis could be made without further delay.In this survey, 40% of the HCPs in private pharmacies 
were able to identify the fictitious case as a possible TB patient. This proportion is higher than the 18% 
reported in a previous study in Ho Chi Minh City, Viet Nam (⩽2 test, P < 0.01) (11). A possible explana-
tion is that we provided more TB-associated symptoms and not only those of 2 weeks’ cough and fever. 
Only about 30% of the HCPs knew that treatment given by the NTP was free, but those who did were 
fi ve times more likely to recognize TB and refer the patient to a TB facility. This suggests that HCPs 
who were aware about the NTP’s free treatment policy performed better with regard to TB control. 
A possible explanation may be that these HCPs were willing to refer because they knew of the NTP 
policy, while the remaining HCPs, including those who claimed to know about the NTP, may not have 
known how to refer a TB suspect. Their decision was therefore drug prescription, referral to general 
hospitals or even suggestion to stay at home. The 30% awareness among HCPs about the free NTP 
treatment policy is lower than that reported in community-based surveys (19-21). Question four in the 
interview did not directly mention the free NTP treatment to avoid bias and that may be the reason for 
this difference. Our finding suggested that 70% of the HCPs in private pharmacies should be provided 
with more information about NTP policy in order to improve referral and prevent TB diagnosis delay. 
A surprising result of the multivariate analysis is that GPP-certified pharmacies were less likely to refer 
simulated patients to TB facilities than non-GPP certified pharmacies (OR 0.10). Vietnamese guidelines 
for GPPs recommend referral of patients with community-acquired diseases to general health care. 
Chapter 2
Suspected Tuberculosis Case Detection and Referral in Private Pharmacies in Vietnam
15
Furthermore, the average work experience in the GPP group was 1.4 years less than that of the non-
GPP group, although the difference was not statistically significant (t-test, P = 0.17), and their  knowl-
edge about NTP may be different. GPP pharmacies were therefore more likely to refer TB suspects to 
general health care. These findings suggest that GPP guidelines could provide more information on TB 
control and additional procedures for referral of TB suspects. The present study has a number of limi-
tations. First, approximately half of the pharmacies randomly taken from the list could not be found, 
possibly because the private pharmacy network in Hanoi was changing rapidly at the time of the survey 
and the registration systems of health authorities had not yet been updated. Second, only two thirds 
of the private pharmacies that were found agreed to participate. The lack of cooperation by the other 
pharmacies may be due to the misunderstanding of the HCPs about the purpose of this research. The 
higher than expected number of pharmacies that remained unidentified or declined to participate may 
have affected the representativeness of our findings. 
ConClusions
Less than half of the HCPs in private pharmacies could detect TB in a suspected patient, and a modest 
proportion of these referred a TB suspect to a designated TB facility where a diagnosis could be made 
without delay. Knowledge about free NTP treatment was a predictor for better TB case detection and 
referral; this could therefore shorten diagnostic and treatment delays. 
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Good pharmacy practice 30 (23) 1 (10)
Non-good pharmacy practice 98 (77) 9 (90)
Sex 
Male 20 (16) 1 (10)
Female 108 (84) 9 (90)
Age (years) 26 (23-37) 26 (23-39)
Degree
Pharmacist 12 (9) 2 (20)
Assistant pharmacist 86 (67) 6 (60)
Drug seller 22 (17) 1 (10)
Training as assistant pharmacist 3 (2) 1 (10)
Medical doctor 1 (1) 0
Nurse 2 (2) 0
No answer 2 (2) 0
Work experience in private pharmacy (years) 4 (2-10) 4.5 (2-10)
Categorical variables are presented as number (%); continuous variables are presented as median (interquartile range)
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Table 2. Response of the healthcare providers in the simulated patient method and the interview
Main group (n = 128) Subgroup (n = 10)
n Percentages (95% CI) n (percentages)
Response to the simulated patients
Sell drugs (#) 68 53 (44.9-61.3) 3 (30)
Antibiotics 53 41 (33.3-49.5) 2 (20)
Cough suppressants 30 23 (16.5-30.4) 3 (30)
Anti-inflammatory/allergy drugs 16 13 (7.1-17.9) 2 (20)
Others 12 9 (4.6-14.2) 0
Rest at home 1 1 (0.0-2.2) 0
Refer for diagnosis 59 46 (37.9-54.3) 7 (70)
Refer to General healthcare 48 38 (29.5-45.5) 4 (40)
Refer to TB healthcare 11 9 (4.0-13.2) 3 (30)
Response to the fictitious case
Sell drugs (#) 58 45 (37.1-53.5) 2 (20)
Antibiotics 51 40 (31.8-47.9) 2 (20)
Cough suppressants 37 29 (21.4-36.4) 2 (20)
Anti-inflammatory/allergy drugs 31 24 (17.2-31.3) 1 (10)
Others 10 8 (3.4-12.2) 0
Refer for diagnosis 70 55 (46.5-62.9) 8 (80)
Possible diagnosis for fictitious case (#)
Pneumonia 58 45 (37.1-53.5) 6 (60)
Tuberculosis 51 40 (31.4-48.3) 4 (40)
Bronchitis 50 39 (30.6-47.5) 3 (30)
Sore throat 7 5 (1.7-9.2) 0
Others 40 31 (23.6-38.9) 2 (20)
Aware of NTP 
Yes 103 80 (73.9-87.0) 10 (100)
No 25 20 (13.0-26.1) 0
Know s NTP’s free treatment 
Yes 34 27 (19.3-33.8) 4 (40)
No 94 73 (66.2-80.7) 6 (60)
Others: all answers mentioned with frequency of less than 5%; (#): Multiple responses may occur;
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Table 3. Predictors for the decision to refer and the ability to detect tuberculosis cases (n=138)(#)
Refer simulated patient to TB hospital Detect TB in paper fictitious case
n (%) OR (95%CI) n (%) OR (95%CI)
Aware of free treatment in NPT
No 5/100 (5) 1 29/100 (29) 1
Yes 9/38 (24) 5.80 (1.88-19.62) 26/38 (68) 5.14 (2.36-11.73)
GPP/non-GPP pharmacies
Non-GPP 14/107 (13) 1
GPP 0/31 (0) 0.10 (≤0.01-0.79)
(#): Combination data from main group and subgroup was analysed








Response to the 
paper fictitious case
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absTraCT
Private pharmacies play an important role of a public-private mix strategy in vietnam, but 
their role in storing and dispensing anti-tuberculosis drugs is not sufficiently understood.  in 
this study on 138 private pharmacies we describe the availability of anti-tuberculosis drugs 
and dispensing practices. anti-Tb drugs presented more frequently in pharmacies located 
near two tuberculosis hospitals. rifampicin was found in about 83% of private pharmacies, 
and about half were dispensed for indications other than tuberculosis. During interviews, 49 
(35.5%) private pharmacies were willing to dispense fluoroquinolones for suspected tuber-
culosis patients. eight pharmacies actually dispensed fluoroquinolones to simulated tuber-
culosis patients. such improper dispensing of anti-Tb drugs in private pharmacies deserves 
more attention.
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inTroDuCTion
Vietnam is a high-burden tuberculosis (TB) country with an estimated incidence of 180,000 tubercu-
losis patients per year [1]. Hanoi is the second largest city in Vietnam, with a population of 3,000,000 
and an estimated TB prevalence of 146 per 100,000 persons [2]. Previous studies conducted in Ho Chi 
Minh City, the largest Vietnamese city, showed that private pharmacies contributed substantially to 
the dispensing of anti-TB drugs [3]. The public-private mix (PPM) strategy, which is aimed at strength-
ening the cooperation between the National Tuberculosis control program and other private sectors, 
incorporated private pharmacies as a setting to refer TB suspected patients for diagnosis [4]. Whether 
private pharmacies could provide more in the PPM project remains an open question though. In 
Hanoi, previous studies addressed that self-prescription, especially with antimicrobial drugs, was very 
common in private pharmacies [5,6]. The consequence of this practice for TB control in Vietnam is 
currently unknown. However, we do know that fluoroquinolone-resistant strains have developed due 
to the empirical use of fluoroquinolones for indications other than TB [7]. Furthermore, the association 
between the Beijing genotype of Mycobacterium tuberculosis and higher fluoroquinolone resistance 
has been shown in a recent research in Vietnam [8]. As fluoroquinolones play a crucial role in the treat-
ment of multidrug-resistant TB (MDR-TB) and fluoroquinolone resistance can develop extensively 
drug-resistant TB (XDR-TB), dispensing of these drugs deserves more attention and caution. Our stud-
ies aimed to explore the availability of anti-TB drugs in private pharmacies in Hanoi and the highlighted 
aspects in the dispensing of drugs to suspected TB patients.
PoPulaTion anD meThoDs
The study consisted of a simulated patient method followed by an interview in private pharmacies 
in Hanoi, Vietnam. Thirteen pharmacies within a 500-meter radius from two TB hospitals in Hanoi 
(National Hospital for Lung Diseases and Hanoi Tuberculosis and Lung Disease Hospital) were col-
lected to become a subgroup. From the remaining pharmacies, a sample of 125 was randomly taken as 
main group. The simulated TB patient (either a student or personnel of Hanoi University of Pharmacy) 
came to the pharmacy and complained about coughing and fever for four weeks with no improvement 
after two 10-day courses of antibiotics (amoxicillin followed by spiramycin). The simulated patient had 
contacted a TB patient, and suggested he could have TB. Then anti-TB drugs were requested. After 
that, an interviewer visited the private pharmacy and described a case: a 50-year-old male had suffered 
from coughing and fever for four weeks without improvement after a 10-day course of spiramycin. The 
interviewer asked what drugs may be dispensed for the described case. After the case detection, the 
interviewer asked what anti-TB drugs were available in the pharmacy with the help of a list with generic 
and brand names. Pharmacists who stored only rifampicin among first-line anti-TB drugs were asked 
about the dispensing purpose. The willingness to dispense fluoroquinolones for the described case 
was also explicitly questioned.
resulTs
The study showed a high presence of first-line anti-TB drugs in the subgroup of private pharmacies, 
which were nearby the two TB hospitals. In other private pharmacies of the main group, first-line 
anti-TB drugs were less available, except for rifampicin. All pharmacies of the subgroup and 104 (83%) 
pharmacies of the main group had rifampicin in stock. Drugs for an MDR-TB indication were more 
frequently present in pharmacies near TB hospitals. These drugs, except for fluoroquinolones, were 
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uncommon in the main group and the mentioned purposes of dispensing were not TB. Fluoroquinolo-
nes were commonly available in private pharmacies. They were told to be dispensed for numerous 
indications but not for TB. Other anti-TB drugs (para-aminosalycilic acid, cycloserin, clofazimine and 
linezolid) were not available in private pharmacies (Table 1). Fifty-one pharmacies (37%) stored only 
rifampicin, whose most common purpose is to cover open wounds (84%). 
Forty-nine (36%) interviewees claimed that they were willing to dispense fluoroquinolones for the 
suspected patient in the interview. Eight (5.8%) pharmacies sold fluoroquinolones to the simulated 
patient. The dispensed fluoroquinolones were ofloxacin, levofloxacin and gatifloxacin (Table 2). Most 
private pharmacy workers (136, 99%) were aware that prescriptions were required to dispense anti-TB 
drugs.
DisCussion
Our study showed different patterns of availability of anti-TB drugs stored in private pharmacies in 
Hanoi. Anti-TB drugs were more common in the private pharmacies near the two TB hospitals. This 
result suggests that the PPM program should encourage participation of these pharmacies in dispens-
ing and monitoring the treatment of TB patients rather than referring suspected patients only [4]. 
The higher presence of rifampicin than other first-line anti-TB drugs suggests that it was there for pur-
poses other than TB treatment. This was confirmed by the in-depth question: pharmacies solely stored 
rifampicin to dispense it for covering open wound infections. The risk of emerged drug-resistant TB 
from that practice might be low because it is used only locally. However, in a high TB-prevalence urban 
area like Hanoi, this risk is cannot be excluded [2]. 
No self-prescriptions containing TB drugs were initiated for simulated suspect patients and the case in 
the interviews. It is likely that the private pharmacies would not initiate treatment of TB if there were 
no confirmed diagnosis for it [3]. This was also confirmed by the high percentage (99%) of private 
pharmacists who were aware that a prescription is required for dispensing anti-TB drugs. Despite of 
this positive information, our results discovered that about 35% of pharmacies were willing to dispense 
fluoroquinolones to the case in the interview. It was not specified which fluoroquinolone they would 
be willing to dispense. However, in the simulated patient method the fluoroquinolones actually sold 
without prescription were ofloxacin, levofloxacin and gatifloxacin. According to the WHO guideline, 
these drugs play a crucial role in the treatment of MDR-TB [9]. Previous studies showed that empirical 
treatment with a fluoroquinolone not only delayed treatment for tuberculosis but also associated with 
a poor prognosis and developed fluoroquinolone-resistant M. tuberculosis strains [7,10]. Also, stud-
ies from Vietnam suggest that Beijing genotype of Mycobacterium tuberculosis, which has a higher 
potential of transmission, was significantly associated with high-level fluoroquinolone resistance [8]. 
To avoid the risk of emerged resistance to such back-bone drugs, we highlight the need to preclude 
the self-prescription of fluoroquinolones in private pharmacies, at least for patients with symptoms 
that highly suggest TB.
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Table 1. Availability of anti-TB drugs in private pharmacies
Main group (n=125) Subgroup (n=13)
n (%)




Rifampicin 104 (83) 13 (100)
Isoniazid 36 (29) 11 (85)
Streptomycin 39 (31) 12 (92)
Pyrazinamid 23 (18) 11 (85)
Ethambutol 33 (26) 11 (85)
FDC 8 (6) 9 (69)
Levofloxacin 55 (44) 12 (92)
Gatifloxacin 32 (26) 5 (38)
Moxifloxacin 13 (10) 3 (23)
Ofloxacin 54 (43) 4 (31)
Amikacin 14 (11) 0 12 (92) 8
Kanamycin 5 (4) 2 10 (77) 9
Capreomycin 1 (1) 0 0 (0) 0
Ethionamide 3 (2) 1 4 (31) 4
Prothionamide 1 (1) 1 3 (23) 3
(*): Mentioned to dispense for TB indication.
FDC: Fixed dose combination 
Drugs that were not available: para-aminosalycilic acid, cycloserin, clofazimine, linezolid.
Table 2. Dispensing of fluoroquinolones during simulated patient method and reason for storing rifampicin (n=138)
n (%)
Willing to dispense fluoroquinolones for case in interview 49 (36)




Stored only rifampicin 51 (37)
For cover open wound 43 (31)
For prescription 3 (2)
Others(*) 5 (4)
Knows that prescriptions are required for anti-TB drugs 136 (99)
FQs: fluoroquinolone; (*): frequency less than two
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Tuberculosis (Tb) is a high-burden infectious disease, especially in low and middle-income 
countries. The efforts to eliminate this disease are challenged by the emergence of multi-
drug resistance and Tb-hiv coinfection. The cumulative knowledge on pharmacokinetics/
pharmacodynamics of antituberculosis agents has recently encouraged therapeutic drug 
monitoring (TDm) in patient care. however, logistical problems related to conventional 
sampling limit the application of TDm in research-oriented institutions. Dried blood spot 
(Dbs) compared with conventional venous blood sampling has the advantages of easier 
sampling, storage and transportation, thus enabling the application of TDm even in remote 
areas. in addition, Dbs with its lower biohazardous risk can be safely performed in a high 
hiv prevalence area, which also tends to have a high Tb burden. another benefit of Dbs 
sampling is that it requires a smaller blood volume than conventional sampling and is highly 
recommended for application in pediatric Tb. a limitation of Dbs is that additional con-
siderations are required for analysis method development and validation. The accuracy of 
the Dbs method is influenced by a number of factors that need to be thoroughly examined 
in method development and validation. further, the agreement between Dbs and plasma/
serum concentrations is not always understood and further investigations are required.
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inTroDuCTion
In 2008 there was an estimation of 11.1 million TB patients worldwide, totaling 9.3 million incident cases 
with a high mortality of about 1.3 million deaths (1). The emergence of multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) tuberculosis and HIV/TB coinfection is also challenging the global tar-
get of the World Health Organization (WHO) of eliminating TB by 2050 (2). Treatments for such cases 
are affected by incredibly high costs and relatively low cure rates (3). Fortunately there is a growing 
understanding of the link between pharmacokinetics-pharmacodynamics (PK/PD) and the outcome of 
TB treatment. As a result, therapeutic drug monitoring (TDM) with drug dose adjustments based on 
PK/PD is applied more in TB control practice. However, these approaches have been challenged. The 
facilities required to perform PK/PD are advanced and are not available in all regular settings. The idea 
of establishing central, well-equipped laboratories where samples from remote clinical sites can be 
analyzed will make TDM more feasible in resource-limited countries. In this context, DBS sampling is 
more appropriate than conventional blood sampling for a number of reasons (4,5): (1) DBS sampling is 
easy to perform even without trained health care staff and requires no electrical facilities; (2) DBS sam-
ples can be stored and transported without cooling facilities because the drug is normally more stable 
in dried DBS matrix; (3) DBS with a minimal biohazardous risk is a good choice for high-HIV epidemic 
populations; (4) DBS requires small amounts of blood, making it suitable for pediatric TB; (5) DBS can 
be used for genotyping and facilitate large epidemiological pharmacogenetics studies.
Besides the advantages listed above, DBS also has drawbacks. The analysis of DBS samples normally 
requires more complex method development and validation process than conventional blood sam-
pling. The influence of blood properties, sampling paper characteristic and method of extraction must 
be carefully examined. The agreement or correlation between analytical results from DBS and plasma, 
serum or whole blood samples are not always assured for all drugs, hence the clinical validation should 
be thoroughly investigated in order to properly interpret these results. Information about using DBS 
for antituberculosis drugs is still limited, therefore more research needs to be conducted in this area.
The present article will explore the options of DBS in TB treatment optimization, and underline con-
siderations for developing and implementing a DBS sampling and analysis method for this purpose.
benefiTs of DrieD blooD sPoT samPlinG for oPTimizaTion of 
Tb TreaTmenT
Therapeutic Drug monitoring for Tb Treatment 
Short-course chemotherapy, which actually can take as long as 6 months or more, has been effectively 
used for newly diagnosed tuberculosis patients with a relapse rates of less than 5% in several clinical 
trials (6,7). The WHO has promoted “Directly Observed Therapy” (DOTS), which monitors patients’ 
treatment adherence, is a cost-effective way to improve treatment outcome, and is especially rec-
ommended for patients at risk of non-compliance (8,9). However, something looks amiss with the 
recent treatment strategy because therapy outcomes were not reproducible for all DOTS programs 
in high-burden countries, where success rates widely vary from 56 to 94% (10). In addition, MDR-TB 
and XDR-TB will become a global threat if there are not enough efforts to prevent the spread of highly 
adapting Mycobacterium tuberculosis strains (11). While the number of available antituberculosis agents 
is limited and most agents have been launched for decades, several new drugs for the treatment of 
tuberculosis are still being researched (12,13). Hence we need to optimize the use of the available drugs 
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to improve treatment outcomes and prevent the Mycobacteria from further drug resistance. Recently, 
PK/PD studies have increased the knowledge about optimal treatment for tuberculosis (13-16). Conse-
quently, application of TDM to tuberculosis treatment is encouraged because it provides a clearer sci-
entific approach than the recent “treat and see” practice based on standardized drug regiments (13-17).
TB patients who have persistent symptoms and one positive bacteriological test after 2 months are 
potential candidates for TDM (16,17). This slow response may be a result of the quality of the drug, low 
adherence, malabsorption, drug interaction or the resistance of Mycobacteria. Measuring blood level 
of antituberculosis drugs can detect subtherapeutics and support the treatment decisions of clinicians. 
Low drug blood level result in ineffective pathogen inhibition and the risk of mutation and resistance 
(14,18,19). A study on TDM revealed that 46 and 48% of TB patients had low blood levels of rifampicin 
and isoniazid, respectively. Up to 83% of TDM service users thought it  is valuable (20). Another TDM 
performed on patients with slow response to the treatment found that 52, 59 and 31% had low levels 
of rifampicin, isoniazid and ethambutol, respectively. After dose adjustment, 90% of patients with low 
rifampicin concentration achieved the expected level. 
Diabetic TB patients should also be considered for TDM (17). Ray et al. suggested that a diabetic condi-
tion relates to higher risk of low rifampicin levels. The same conclusion was drawn in another study 
in which rifampicin blood levels in diabetic patients dramatically decreased. (21). However, the reason 
for the lower rifampicin exposure in diabetic patients is still being debated, as no noticeable difference 
was observed in yet another study (22). Because of these inconsistent results, monitoring antitubercu-
losis drug concentrations can ensure the proper therapeutic outcome for diabetic TB patients.
MDR-TB patients can benefit from TDM because many second-line antituberculosis drugs have a nar-
row therapeutic window (23,24). Most recent MDR-TB treatment regiments are take 18 to 24 months 
of treatment with high risk of toxicity. TDM minimizes the toxicity related to high drug concentrations 
through adjustment of the dose. Low drug exposure, which can cause further resistance of MDR-TB, 
can also be detected.
The risk of developing active TB as an opportunistic infection is much higher in HIV patients, who can 
also benefit from TDM. The treatment of HIV/TB coinfection faces difficulties due to the high risks of 
drug-drug interaction. The hepatic cytochrome P450 (CYP) enzyme system plays an important role in 
the drug-drug interaction of antiretroviral and antituberculosis agents. The major metabolism of pro-
tease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which contributes 
to the backbone of highly active antiretroviral therapy (HAART), relies on CYP. Rifampicin, the crucial 
agent in TB treatment regimens, is also known as a potential CYP enzyme inducer and can cause sub-
therapeutic levels of PIs or NNRTIs if they are co-administered. As a result, the HIV is not controlled 
effectively and resistance to antiretrovirals also emerges. Indeed, avoidance of PIs is recommended in 
most cases treated with rifampicin due to the dramatically drop in blood levels. With NNRTIs, blood 
levels are less affected by rifampicin but an increased dose of NNRTIs is still required (25). Because 
this adjustment may have an adverse effect on the liver, TDM can be used to optimize the treatment. 
Rifabutin can be used as a substitute for rifampicin because of the smaller influence on CYP enzymes 
(26,27). However, the metabolism of rifabutin is inhibited by PIs and dose adjustment is still recom-
mended (28,29). Besides drug-drug interactions, the condition of HIV disease itself can influence blood 
levels of antituberculosis (25,30-32). A retrospective cohort study showed that low serum levels of 
antituberculosis drugs are common among patients with advanced HIV. Subtherapeutic levels may 
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be due to malabsorption and can be overcome by increasing the dose. For these reasons, TDM is sug-
gested as a potential tool to optimize therapy on this type of patients (32).
TDM is a useful tool for the optimization of TB treatment and improvement of treatment outcome. 
However, its application is still limited in health institutions and high-income countries. In low-income 
countries burdened by high TB rates, TDM seems to be a difficult option because of insufficient facili-
ties and trained technicians. Centralizing facilities and workforces in one or two adequate laboratories 
is a possible solution. The difficulty however lies in how to integrate different clinical sites with the 
analytical laboratory. TDM has recently been using liquid samples, including serum, plasma and whole 
blood as conventional matrices. Venous blood sampling normally requires trained health care staff, 
large blood amounts, complex cooling facilities for storing and transporting samples, and careful pre-
vention of biohazards. DBS that is performed well in a limited setting can minimize such logistical dif-
ficulties (33). DBS has been used for decades to screen biomarkers and monitor treatment outcomes 
of HIV. Thanks to recent precise analytical instruments (e.g. LC-MS/MS), DBS is more widely applied 
in pharmacokinetic studies and TDM (4,34-36). DBS can be attained by spotting small blood drops 
from pricking an adult’s finger or an infant’s heel onto a pure cellulose paper strip (Figure 1). The drug 
concentration is then analyzed after appropriate extraction.
Dbs and Therapeutic Drug monitoring in resource-limited settings
The most attractive aspect of applying DBS sampling is that it can be performed even in limited 
resource areas. First, DBS sampling is quite easy and even patients themselves can perform it after 
a simple instruction by a health care personnel (33). The convenience of DBS sampling is important 
because TB patients without XDR-TB are mostly treated in the community under the DOTS program, 
where trained nurses are not always available to take blood samples. Some studies have been con-
ducted to explore the possibility of patients themselves doing DBS sampling and whether those DBS 
results are reliable. Data from transplant patients using immunosuppressants and diabetic patients 
show that there is no difference from DBS obtained by nurses or by self-sampling at home (37). In 
another study a slight difference was detected when patients took the sample themselves at home 
instead of under supervision at a clinic (38). In terms of tuberculosis control, we noticed that the DOTS 
program is spreading globally, even in rural areas. The person who directly observes the therapy of the 
patient in this program can be trained to take the samples and handle them if the TDM is performed 
in such situations.
Second, DBS sampling does not require electrical apparatuses for centrifuging or a volumetric 
device, therefore it is considered to be highly suitable for a resource-limited setting. Indeed, DBS is 
recommended for monitoring HIV treatment or screening biomedically in anthropology surveillance 
resource-limited settings to overcome the logistical burden of conventional sampling (4,5). These suc-
cessful applications encourage us to think about DBS when designing a population-based pharma-
cokinetic study of tuberculosis agents or setting up a TDM program in the remote area with a high TB 
burden.
Third, differently from serum or plasma which are available as liquid matrices, DBS is stored as a dried 
sample, therefore improving stability (33,36). As a consequence, the DBS sample is easier to handle 
because dry ice for shipment and a freezer for storage is not required. For example, TDM for rifampicin 
and isoniazid has required the plasma sample to be stored immediately at 70°C and transported with 
dry ice to the laboratory within four days of collection (20). Another TDM procedure for antitubercu-
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losis agents reported that serum was immediately placed in a 70°C freezer and then packed in dry ice 
and shipped to the research centre. The results of the TDM were faxed and mailed back to the originat-
ing chest clinic (39). Obviously, these procedures are not applicable in a resource-limited setting and a 
validated DBS method with an appropriate stability assessment can be used as an alternative.
Therapeutic Drug monitoring of hiv/Tb Coinfection 
The application of DBS has been widely investigated in high HIV prevalence. DBS has been recently 
used as an ideal tool to monitor viral load or even generate genotype of the HIV-resistant strain for 
patient care in a resource-limited setting (4,40). Integrating with HIV monitoring programs using DBS, 
additional benefit in patient care can be expected. For that reason, DBS should be further investi-
gated for TDM or pharmacokinetics research on such patients. (40). Most TDM trials on antiretrovi-
rals have been conducted in high-income countries and did not show a clear benefit. It is suggested 
that research be conducted in more appropriate places where the burden of disease is greatest and 
the concurrent epidemics (tuberculosis, HIV, malaria) are available (41). High HIV/TB burden areas 
are commonly resource-limited and the application of DBS for such research should be considered 
(10). Besides the advantages mentioned above, using DBS sampling can minimize the risk of biohazard 
infection. Because it is a dried sample no tube is needed, and the risk of contamination from broken 
samples can be avoided. In addition, viruses like HIV lose their infectivity in dried paper matrix and 
the DBS sample can be packed and transported by regular mail without concerns of handlers being 
exposed to the blood or infectious material (4,33,42).
Dbs and Tb Treatment ooptimization in Pediatrics
Study on pharmacokinetics of antituberculosis drugs in term of infants and children is still required 
(43,44). In the case of tuberculosis treatment, the dosage for children was previously defined extrapo-
lating pharmacokinetics information from adults. The most recent revision of first-line drugs using 
pediatric pharmacokinetic data suggests higher doses than previous recommendations in order to 
get a blood level equal to that of adults’ (45). However, pharmacokinetics data to confirm the appro-
priateness of these new updated dosages is not available and the pharmacokinetics information on 
other antituberculosis drugs is still limited. The WHO recently called for a large population-based 
pharmacokinetic study at the newly recommended dosages and pharmacokinetic studies in infants 
(43). Using large amounts of blood is the ethical barrier currently faced by pharmacokinetic studies 
on pediatrics (46,47). To complete a pharmacokinetic profile, about 10 samples are required. Popula-
tion pharmacokinetics using population-based estimation is a possibility for surmounting this obsta-
cle. Because information from all individuals is merged when estimating population pharmacokinetic 
parameters, the sparse sampling scheme, which requires only one to six time points, can be applied. 
For pharmacokinetic studies on pediatrics, this small number of samples is preferable to the traditional 
intensive sampling scheme which normally requires samples at more than ten time points (47,48). 
However, even with a sparse sampling scheme, the 3 ml of blood per sample required in conventional 
sampling seems too much for children (46). DBS, which requires only about less than 100 µL of blood, 
can be considered as an alternative sampling method. The application of DBS has a long-standing his-
tory since the first collected DBS sample from newborn heel pricks to detect phenylketonuria in the 
1960s (49). This led to several nationwide newborn screening programs for metabolic disease and is 
now applied worldwide (50-52). DBS was also successfully applied in pharmacokinetic studies of anti-
microbial drugs on neonates (53). Because it requires small amounts of blood, DBS should be used in 
pharmacokinetic studies or TDM for children (46).
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Pharmacogenetics for Pharmacovigilance 
DBS samples can be used for genotyping purposes, thus enabling performance of pharmacogenetics. 
The recently clinically validated pharmacogenetic biomarker related to metabolism of rifampicin and 
isoniazid is N-acetyltransferase. In combination with TDM, this biomarker can be a complementary 
tool for optimal individualization therapy (54). De Boer et al. used DBS for genotyping of CYP450 
enzymes from 12 volunteers, observing a 100% match result between DBS and whole blood drawn by 
venipuncture (55). This promising finding, in conjunction with the possibility to apply DBS in remote 
areas, suggest DBS as a potential sampling method for the future application of pharmacogenetics to 
tuberculosis treatment.
DeveloPmenT anD valiDaTion of a DrieD blooD sPoT meThoD
DBS has many advantages but also some disadvantages. Several considerations are required to ensure 
accuracy when DBS methods are developed and validated. Similarly to other bioanalytical methods, 
DBS methods need to be validated in term of selectivity, specificity, linearity, reproducibility, recovery 
and stability. Currently the most accepted guideline for the validation of bioanalytical methods is the 
“Guidance for Industry. Bioanalytical Method Validation” of the U.S. Food and Drug Administration 
(56). DBS analytical results can also be affected by a list of confounding factors, hence extra assess-
ments in the method development and validation need to be considered (33,36).
sampling Paper
There are several paper brands with different characteristics that can be used in DBS sampling. 
Schleicher & Scheull 903 (Whatman 903) has been widely applied in newborn screening and HIV mon-
itoring programs for years (4,52). In genotype HIV studies there was evidence that Whatman FTA Elute 
paper was inferior to Whatman 903 (4). Another paper, Whatman 31 ET-CHR, which is thicker than 
the other two types, was also applicable for a DBS method (57). Regardless of the type of paper used, 
paper types are not interchangeable because the difference in thickness and porosity leads to differ-
ent absorption properties. For that reason, the paper used in DBS sampling needs to match the DBS 
calibration in the laboratory. The uniformity of paper from different batches should also be tested. 
The Newborn Screening Quality Assurance Program applies a procedure in which 125ILThyroxine is 
used to test the homogeneity from each batch (52). A simpler way to estimate the spread of blood on 
the paper is by measuring the size of DBS produced by different blood volumes. The linear correlation 
between the area of DBS and the blood volume can indicate whether the blood spreads equally on the 
paper. (57-59). In some situations the paper can also be treated with an appropriate reagent before it is 
used for sampling in order to improve stability or recovery of the DBS (36,60). However, the consist-
ency of any additive needs to be proved.
sampling method and extraction
There are two approaches for DBS sampling. The first method (method 1) uses a precise volumetric 
device (e.g. pipette) to withdraw capillary blood from a finger prick and transfer to paper in order to 
make the blood spot. The whole DBS is then cut or punched out for analysis (61-64). Because the blood 
volume has already been precisely defined in each blood spot, errors caused by the non-uniformity of 
the paper, hematocrit, chromatographic effects or blood volume of the spot can be neglected. In the 
second method (method 2), the blood volume in a DBS does not need to be precise because a fixed 
diameter disc from a part of the DBS is punched out for analysis. In most cases, the DBS is produced 
by directly dropping blood from a finger prick onto the paper (57,58,65-67). This approach is more con-
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venient for DBS sampling in a resource-limited setting where volumetric devices are not available or 
cannot be easily handled by untrained personnel. The drawback of this technique is that the effect of 
blood volume variation on the accuracy of the assay needs to be further examined. An improved way 
to generate DBS is by withdrawing blood from a finger prick into an anticoagulant-treated capillary and 
subsequently spotting on the paper. Using the capillary can help the technician control the blood vol-
ume better than directly dropping blood from a finger prick. Despite the improved work flow and the 
more consistent blood volume in the DBS, using a capillary might be not very convenient in settings 
with limited resources. Because a fixed diameter disc from one part of the DBS is used for analysis, this 
approach should be similar to method 2 (55).
Recent DBS sampling as described above applies mostly to off-line extraction, which is time-consum-
ing and labor-intensive, and sometimes requires many manual procedures (36). For that reason, on-
line extraction has been introduced as an effort to improve the throughput of the DBS analysis. The 
first introduced on-line elution system integrated an extraction cell with an extraction column for 
purification and an LC-MS/MS system (68,69). This on-line extraction however still required a manual 
step to punch the disc out and place it in the extraction cell. The other concept is to directly elute one 
part of the DBS with the help of a clamp module or a thin-layered chromatography mass spectrometer 
interface (TLC-MS) (70,71). These instruments do not require the punching step. The integration with 
an auto-sampler system using a standardized DBS card enables the totally automatic analysis (35). 
Nevertheless, it should be noticed that these on-line extraction instruments are still being developed. 
Improvement and more data are needed to prove their validity in practice. The DBS extraction proce-
dures are presented in Figure 2.
blood Properties
Beside the convenience of DBS sampling in a resource-limited setting, the drawback of method 2 is the 
occurrence of analytical biases caused by hematocrit, blood spot volume and chromatographic effect 
(33,36). Hence these factors should be considered in method validation. The accepted biases should be 
within the criteria in bioanalysis of 15% (56). These biases can be neglected if the DBS analysis follows 
method 1, as the entire DBS is used for analysis.
hematocrit
The hematocrit of patients varies between individuals. Because hematocrit accounts for the propor-
tion of blood cells in the whole blood, it contributes to its viscosity. With higher hematocrit the spread 
of blood is limited, resulting in a smaller DBS than with lower hematocrit. (57,59). Because a fixed 
diameter disc is punched out, the actual blood amount in a disc with higher hematocrit is larger too. 
The analytical biases between different hematocrit blood could thus be observed (57,59,72,73). For that 
reason, the hematocrit of calibration DBS samples should be standardized at a specific value (33). The 
hematocrit of a tuberculosis patient is approximately 35 ± 6%, a little bit lower than a healthy person’s; 
a standardized hematocrit value of 35% can thus be selected (74,75). A validation using quality control 
samples with hematocrit ranges from 20 to 50% (e.g. ± 2 standard deviations) should show an accept-
able bias of less than 15% for quantitative bioanalysis (56). The blood with hematocrit largely differs 
from standardized value, can produce a high bias, and the correction for hematocrit may improve the 
accuracy of the method. Vu et al. developed an equation for the correction of analytical results for 
hematocrit. Normally, hematocrit is part of routine laboratory tests for patients with tuberculosis and 
can be used for this correction (57). However, the acceptability and the application of this correction 
method in clinical practice should be further investigated and validated
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To prepare calibration and quality-control samples for DBS analysis, blood with a defined hematocrit 
value is required. This blood can be prepared by removing or adding appropriate volumes of plasma 
from the blood (59,76). Another method is washing the red blood cells by physiological buffer and 
subsequently mixing with plasma (57,77). It must be noticed that the reverse pipette technique should 
be used to transfer a precise volume of a high-viscosity suspension like whole blood or red blood cells. 
This technique can reduce errors due to film retention.
Chromatographic effect
The diffusion of blood over the paper may be non-homogenous. Holub et al. found that several amino 
acids have different concentrations between the central and the peripheral parts of the DBS. To test 
this effect, analytical results from 3-mm discs punched out from the central and the peripheral parts of 
the DBS were compared (78). Another approach used different punch sizes, verifying if the concentra-
tions show a linear correlation with the areas of the punched discs (66). As long as the analytical biases 
of different punches to nominal concentrations are less than 15%, the chromatographic effect can be 
neglected.
blood volume of the spot
A punch diameter between 3 and 8 mm is commonly used for the DBS analysis following method 2 
(33,36). It is important that the punch disc be small enough to be fully filled by blood and large enough 
to ensure acceptable assay sensitivity. In a resource-limited setting where no volumetric capillary 
device is available, the blood spot size may tend to vary and analytical bias may be introduced as a con-
sequence (79). The biases caused by the variation in blood spot volumes can be partly explained by the 
chromatographic effect because the disc punched out from smaller DBS will contain more peripheral 
parts (57). If the drug is more concentrated in the central part, the smaller DBS seems to introduce 
negative bias. However, this effect is not very common with recent developed DBS methods (57,79). 
matrix effect and recovery
The common instruments used for DBS analysis are immunoassay, gas or liquid chromatography inte-
grated with UV detectors, and tandem mass spectrometry. One has to keep in mind that cellular com-
ponents (e.g. protein, hemoglobin, Fe2+, etc.) present in DBS can produce significant matrix effects. 
Takashi et al. observed a significant bias due to hemoglobin when a DBS method for gentamicin using 
immunoassay was developed (76). With mass spectrometry, the matrix effect is an even more com-
plex aspect. In this case, either ion suppression or enhancement may happen and this needs to be 
examined in method validation (36,56,80). If the reproducibility of the method is potentially affected 
by the matrix effect, liquid-liquid extraction (LLE) or solid phase extraction (SPE) can be applied. LLE 
or SPE can effectively eliminate the endogenous component in DBS, therefore improving the repro-
ducibility of the method (81-83). Because the analyte of interest needs to be extracted from the DBS, 
both in the on-line or off-line extractions, the recovery of the extraction needs to be evaluated. The 
validated procedure in off-line extractions should be carefully complied with by the analysts because 
non-standardized performance may introduce assay errors. In our laboratory we experienced that DBS 
can be gradually extracted without any stimulation like sonication or vortex. If the DBS is not discarded 
after extraction or the extracts are withdrawn at different times, the recovery may be not reproduc-
ible. A summary of how to evaluate the matrix effect and recovery in a DBS method can be found in 
another review (36).
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stability in relation application in remote areas
As mentioned before, one of the most attractive aspects of DBS sampling is that it can overcome logis-
tical problems, which is challenging conventional sampling methods. For that purpose, it is expected 
to store and transport DBS at normal temperatures without dry ice or freezer. Nevertheless, using 
DBS is not the solution for all problems. First, some molecules are not stable in the dried matrix of 
DBS even at low temperatures (84). Second, regular shipping sometimes introduces extreme environ-
mental conditions, including high temperature and high humidity. Such conditions can stimulate the 
degradation of DBS (33,36). For that reason, the stability of any DBS method needs to be thoroughly 
validated under all possible conditions happening during storage and transportation.
effect of Temperature
Temperature is the most noticeable factor that needs to be investigated and carefully controlled, oth-
erwise it may limit the application of DBS to a certain extent. Some antituberculosis agents such as iso-
niazid are not stable in plasma even at 200C (85). In such situations, the conventional sample is difficult 
to handle, even in well-equipped settings. Using DBS may help the samples to become more stable. 
Several problems remain though, as some substances are not stable in DBS even at cool temperatures 
of 4°C and hydrolysis occurs even during DBS drying time (84). For that reason, examination the stabil-
ity of the whole blood during drying time of the DBS  should be performed. The drying time depend 
on the amount of blood, paper type and the environment condition like humidity, temperature (33,36). 
The stability can still be improved by adding inhibitors. The antimalaria agents amodiaquine and lumefan-
trine are not stable in either plasma or DBS at room temperature (83,86). Consequently, application to 
the field setting was limited. Ntale et al. introduced an improvement in which phosphoric acid was added 
to the blood before producing a DBS in order to prevent the oxidation. With this adjustment, lumefan-
trine was stable for 3 months and amodiaquine was stable for at least 4 months at the room temperature 
of 25°C. In this way, sampling of these antimalaria agents in the field becomes more feasible (61,62).
Many high-burden tuberculosis countries and resource-limited settings have tropical environments 
with high temperatures. This should be taken into account when validating for stability before apply-
ing the method. For TDM in remote areas, DBS samples are expected to be transported by mail. As 
temperatures in a postal box can reach 60°C, this condition should be tested too (33). The duration of 
the stability test needs to be defined based on real conditions. Extreme temperatures up to 60°C may 
not present for the whole duration of the sample shipment, therefore a short term of 3 days of stability 
is considered appropriate (60). Another way to examine stability conditions is to send DBS samples 
by post and measure the subsequent degradation (37,87). Recently, battery powered temperature and 
humidity monitors are applied in the transportation of plasma sample. This device can be used to 
examine the condition of DBS shipment. The information about shipment temperature and humidity 
is useful to figure out which conditions should be test in the validation of stability.
effect of the humidity
Another noticeable factor that needs to be controlled is humidity. In some field settings humidity is 
very high, even reaching saturation. Humidity can activate hydrolysis or enable the growth of micro-
organisms (36). In addition, high humidity requires longer drying time, which can induce degradation. 
Using heat or light for drying acceleration can be a solution but not for thermo-unstable agents (88). 
Humidity should be avoided by storing in waterproof plastic bags with desiccant sachets. A humidity 
indicator should be added to the bag also (33,36).
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aPPliCaTion of Dbs for CliniCal use
relationship between Concentrations from Dbs and Conventional method
As mentioned, introducing DBS to the optimization of tuberculosis treatment is attractive and can be 
considered as a promising tool in patient care. With certain drugs such as immunosuppressants and 
antimalaria agents, the pharmacokinetic studies or TDM were based on venous whole blood concen-
trations, which are supposed not to be very different from DBS concentrations (37,89-92). However, 
for other drugs, the recent available pharmacokinetics data is based on plasma or serum concentra-
tions. As a consequence, dose optimization should also use the conventional sampling method. To 
apply DBS in that case, one should consider the possible differences between the concentrations in 
DBS and in plasma/serum. Besides the random error due to analytical instrument error, a number of 
potential technical and physiological confounders may result in biases among drug concentrations in 
venous plasma (Cplasma), venous blood (Cvenous blood), capillary blood (Ccapillary blood) and DBS (CDBS).
The bias between Cplasma and Cvenous blood (D1) is introduced due to the different extents of the partition 
between erythrocytes and plasma. In addition, individual hematocrit variations also result in this kind 
of bias. Normally, the blood/plasma ratio (B/P) depends on hematocrit while the erythrocyte/plasma 
ratio (E/P) is independent from it (93,94). It should be remarked however that when plasma protein 
binding and/or erythrocyte binding sites are saturated, the nonlinear kinetics of the erythrocyte parti-
tion appear. As a consequence, in that case the E/P and B/P will not be constant over the investigated 
concentration range (95). The available data on the influence of pathological and demographic factors 
on the B/P are limited. Disease, gender, age, genetics and co-medication may be factors that also con-
tribute to the variation of B/P (93,95).
Besides the extent of B/P partitioning, the rate of partition may also cause disagreement between 
Cplasma and Cvenous blood. Partitioning equilibrium is rapidly achieved for most of the drugs, therefore it 
can be neglected. However, some drugs require hours to reach the equilibrium, so the agreement 
between blood and plasma concentrations will not be warranted (96). Drugs with high binding affin-
ity for plasma proteins or erythrocytes and with low cell membrane permeability are potential can-
didates for partitioning delay (95). Information about the partitioning of drugs between blood and 
plasma is limited so far. This information is important for the development of DBS method because it 
allows researchers to predict whether a method is applicable (97). A small in vitro experiment can help 
roughly estimate this factor. 
The bias between Cvenous blood and Ccapillar blood (D2) may also be a source of error. The capillary blood from 
a finger prick may be contaminated by interstitial or intracellular fluid. It has been therefore suggested 
that the first drop of blood be discarded. Pressing the finger to collect more blood should also be 
avoided because it may introduce more contaminating fluid. Warming the finger with warm water 
can facilitate the blood flow and enable easier DBS sampling (33). However, the warm water may also 
change the circulation of capillary blood and its properties as a consequence and should be examined 
too. Capillary blood is a mixture of arteriolar and venous blood, and comparable results between two 
sampling sites are not always expected. Spooner suggested that the concentration for capillary blood 
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should be between the concentration of arterial and venous blood. The distribution of some drugs 
among extravascular tissue, arterial and venous system may be delayed and cause the difference of 
venous and capillary blood. (46,93,98). It was reported that concentrations of paracetamol in finger-
prick DBS were significantly different than those in venous DBS taken at the same time. (98,99). How-
ever, no significant differences were observed for other drugs like tacrolimus, everolimus clozapin or 
moxifloxacin (37,57,60,100). 
Factors that influence the difference between Ccapillary blood and CDBS (D3) are mainly introduced by the 
sampling technique. The hygienic solvent should be dried at the puncture site to avoid hemolysis or 
sample contamination (33). Viscosity, paper type and chromatographic effect, which were mentioned 
above, may also contribute to this kind of error. 
Clinical validation 
Because many factors can potentially influence the difference between the DBS and plasma concentra-
tions, it is recommended that a DBS method be validated on actual patients (33,36). The purpose of 
clinical validation is to demonstrate the agreement or the correlation between the DBS and plasma 
concentrations. With a sufficient correlation, appropriate interpretation of DBS results to plasma or 
whole blood is possible and can be used for clinical decisions. In clinical validation, the drug concen-
tration in DBS and other conventional samples taken at the same time are measured and compared 
by using a linear regression analysis. A high correlation coefficient suggests that the results between 
methods can be interchangeable (101). However, to explore the agreement of different methods, the 
comparison method using Deming regression or Pasing-Bablok regression is preferable (90,102). These 
kinds of regressions take into account the errors from both test and reference analytical methods 
instead of the error from only test methods used in ordinary linear regression (103). The slope of the 
regression line is compared to 1 and the intercept is compared to zero. The slope is different from 1 if 
DBS and plasma concentrations are different. The uneven plasma-blood cell partitioning is a potential 
reason for this kind of difference. Regardless of the regression method used, a nonlinear regression can 
be observed if there is a nonlinear partitioning kinetic in which E/P ratio is not constant over the inves-
tigated concentration range. In that case, the interpretation from DBS concentration to plasma results 
seems to be complex. Another way to evaluate the agreement between two concentrations is using 
Bland Altman plot. In this method, the differences between two concentrations are plotted against the 
average concentrations. The average of the differences was compared to zero to show the bias, and the 
95% limit of agreement presents the variation between two concentrations (90,98,100,101). Another, 
more clinical approach is to evaluate the agreement of pharmacokinetics information attained from 
DBS and venous blood concentrations. Cheung et al. used Bland Altman plot to compare the area 
under the concentration time curves of tacrolimus constructed by DBS and whole blood results (89). 
The bias of 8.3% between the result from the two samples is considered to be acceptable, therefore 
the DBS result can be used to estimated tacrolimus concentration in the whole blood.
DrieD blooD sPoT meThoD for anTiTuberCulosis aGenTs
Up till now, there has been a limited number of publications about the DBS method for antituberculo-
sis agents. Allanson et al. have developed a method to determine rifampicin in DBS by using HPLC with 
UV detection. Rifampicin from DBS was extracted using acetonitrile and ammonium acetate buffer. 
There was no degradation, neither in the DBS nor in the post-preparation solution within 9 hours 
(67). The same research group also put their efforts into developing a method to determine isoniazid 
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and pyrazinamide in DBS based on gas chromatography-mass spectrometry. The primary result was 
promising with pyrazinamide but the oxidation was observed with isoniazid. The instability of iso-
niazid should be noticed when developing and validating a DBS method for this drug (104). Another 
publication found is about determination of moxifloxacin, an antituberculosis agent for MDR-TB, in 
DBS using LC-MS/MS analysis. The method was validated and can be used in future pharmacokinetics 
studies or TDM (57). 
The correlation between DBS and plasma concentrations of rifampicin has been tested in five patients 
and shown to be linear. The slope of 0.72 suggests that the concentration in DBS is lower than in 
plasma, and that more rifampicin distributes in plasma (67). With another antituberculosis agent, 
moxifloxacin, the slope of Passing Bablok regression line was 1.49 (90%CI:1.32-1.77, n=18). This reveals 
that moxifloxacin has a higher affinity for blood cells than for plasma (57). Correction for these distri-
bution factors is required to interpret the DBS results to plasma concentrations for clinical purposes. 
Future development of more DBS methods for the other antituberculosis agents and applying DBS to 
TB treatment optimization may prove the further validity of this method.
ConClusion
Application of dried blood spots sampling for the optimization of tuberculosis treatment might be the 
solution for overcoming the obstacle of conventional sampling. In comparison to conventional sam-
pling methods, DBS sampling is easier to perform in a resource-limited setting and easier to transport 
to the laboratory. These advantages enable TDM even in rural areas with an existing demand for this 
service. In addition, DBS sampling is preferable for TDM of TB drugs in pediatric patients because it 
requires small amounts of blood, which is more acceptable than in conventional sampling. However, 
additional considerations are required when applying this method in daily practice. The accuracy of 
the method may be affected by many factors, including paper type, blood characteristics, analysis 
method and the characteristic of drugs themselves. Clinical validation of this method is required for 
the interpretation of DBS concentrations into serum or plasma concentrations. In the future, more 
DBS methods for antituberculosis agents should be developed and applied to patient care.
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Figure 1. Dried blood spot sampling from a tuberculosis patient (following method 2)
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Figure 2. Dried blood spot extraction and analysis
IS: internal standard
HPLC-UV: high-performance liquid chromatography – ultraviolet detector
GC: gas chromatography
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absTraCT
moxifloxacin (mfX) is a potential oral agent use in the treatment of multidrug-resistance 
tuberculosis (mDr-Tb). Due to variability in pharmacokinetics and in vitro susceptibility of 
causative bacteria, therapeutic drug monitoring (TDm) of mfX is recommended. Conven-
tional plasma sampling for TDm is facing logistical challenges, especial in limited resource 
areas, and dried blood spots (Dbs) sampling may offer a chance to overcome this problem. 
The objective of this study was to develop a lC-ms/ms method for determination of mfX 
in dried blood spots (Dbs) that is applicable for TDm.
The influence of paper type, the hematocrit (hct) and the blood volume per spot (vb) on 
the estimated blood volume in a disc (vest) was investigated. The extracts of 8mm diameter 
discs punched out from Dbs were analyzed using liquid chromatography tandem mass spec-
trometry (lC-ms/ms) with cyanoimipramin as internal standard. The method was validated 
with respect to selectivity, linearity, accuracy, precision, sensitivity, recovery and stability. 
The effect of hct and vb on lC-ms/ms analytical result was also investigated. The relation-
ship between mfX concentrations in venous and finger prick Dbs and those in plasma was 
clinically explored.
vest was highly influenced by hct while the effect of vb appeared to be different among paper 
types. Calibration curves were linear in the range of 0.05-6.00 mg/l with inter-day and intra-
day precisions and biases of less than 11.1%. The recovery was 84.5, 85.1 and 92.6 % in response 
to blood concentration of 0.15, 2.50 and 5.00 mg/l, respectively. a matrix effect of less than 
11.9% was observed. mfX in Dbs was stable for at least 4 weeks at room condition (tempera-
ture of 250C and 50% of humidity). a large range of hct value produced a significant analytical 
bias and it can be corrected with resulting Dbs size. a good correlation between Dbs and 
plasma concentrations was observed and comparable results between venous Dbs and fin-
ger prick Dbs was attained. This fully validated method is suitable for determination of mfX 
in dried blood spot and applicable for TDm.
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inTroDuCTion
Fluoroquinolones play a crucial role in MDR-TB treatment regiment (1). Moxifloxacine (MFX) is one 
of the most promising drug of this group with high in vitro and in vivo activity and is well tolerated 
(2-4). Furthermore, MFX may be useful in extensively drug-resistant tuberculosis (XDR-TB) (5). MFX 
appeared to be effective in shortening tuberculosis treatment if it is added to or substituted for an 
agent in the standard regimen (6). In selected patient populations (e.g. HIV and tuberculosis meningi-
tis), MFX is a potential candidate to become part of the routine treatment (7,8). 
Although MFX is frequently used in the treatment of tuberculosis, the optimal dosage of MFX in tuber-
culosis treatment is not clearly defined (9). The in vitro pharmacodynamic infection model showed 
optimized efficacy using a dosage of 800 mg per day, while 400 mg per day is given in daily practice 
(1,7,9). Furthermore, a significant drop in area under the curve (AUC) of MFX of approximately 30% is 
observed if rifampicin as an enzyme inducer is administered concomitantly (10). Taking these facts in 
consideration, a TDM may help to avoid too low blood levels and to improve the treatment outcomes 
(11). Unfortunately, facilities for determination drug level in remote rural areas are not available.  As 
blood samples are unstable at room temperature and cooled shipment is not feasible, the application 
of DBS sampling is a potential solution to overcome these logistical problems. Although MFX is stable 
in plasma at the room temperature for at least 5 days (12) long distance transport may take more time 
or room temperature may be exceeded during transport. DBS sampling has also other advantages 
including easily to perform; lower risk of infection and the required blood sample volume is smaller 
(13,14).  Although the influence of Hct and volume of the bloodspot (Vb) were emphasized as potential 
confounding factors, these may vary for each drug. Therefore Hct and Vb need to be investigated in 
DBS method development (13-19).
Up to now, DBS method had been developed for the pharmacokinetics and TDM of a number of drugs 
(13,14,20). As DBS proved its value in TDM of HIV drugs it may also help to optimize the treatment of 
tuberculosis (TB), especially with MDR-TB.
Clinical validation is highly recommended for DBS method development because Hct, viscosity, and 
consistence of blood may vary between patients. In the clinical validation the relation between the 
plasma concentration and the concentration of the drug in whole blood (plasma-blood cell partition 
coefficient) can be determined.  The result obtained with  DBS can be translate to the reference value 
which have been determined in serum or plasma value using the blood/plasma ratio (13).
The objectives of our study are to develop a LC-MS/MS method for determination of MFX in DBS, and 




Moxifloxacin hydrochloride was provided by Bayer AG (Berlin, Germany). The internal standard, cya-
noimipramine, was supplied by Roche (Woerden, The Netherlands). Acetonitrile (ACN) Lichrosolve 
and water for LC/MS were purchased from BioSolve (Valkenswaard, The Netherlands). The chemicals, 
including methanol (MeOH) Lichrosolve and trifluoroacetic anhydride, were of HPLC or analytical 
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grade and were obtained from VWR (Amsterdam, The Netherlands). Three types of paper, including 
Whatman 31 ET CHR, Whatman 903 and Whatman N03 were used. The punching machine (punch 
diameter - 8mm)  was supplied by Technical Support Facilities of the University of Leiden (NL) by 
P.M. Edelbroek PhD, (Heemstede, the Netherlands) (13). Packed cells and pooled human serum were 
provided by the Department of Haematology, University Medical Center Groningen according to local 
regulations. 
sample preparation 
Stock solutions of MFX were prepared as stock A and stock B by dissolving MFX HCl in water at con-
centration of 200 mg/L in order to make calibration standards and quality control (QC) samples. The 
stock solutions were diluted to working stock solutions of 10 mg/L (working stock A1 and B1). 
Packed red blood cells (RBC) were centrifuged and the preserving solution was discarded. The subse-
quent cells were washed three times with physiological buffer and one time with serum before adding 
a precise volume of serum to produce pooled blood with the Hct of 20, 35 and 50%.
Calibration blood was prepared at concentrations of 0.05, 0.15, 0.50, 1.00, 2.00, 3.50, 5.00 and 6.00 
mg/L by adding stock solution A or A1. QC samples, including LLOQ (lower limit of quantitation), 
LOW, MED, HIGH, OC (over the calibration curve) at concentration of 0.05, 0.15, 2.50, 5.00 and 10.00 
mg/L, respectively, were prepared from stock solution B and B1 by the same method. All tests for the 
validation were performed using the Hct of 35% except for the evaluation of the Hct effect itself.
To prepare a DBS, 50 µL of  blood was transferred onto paper by an Eppendorf pipette. It was left to 
dry for at least 3 hours at room temperature and then preserved in a sealed plastic bags at -800C. Each 
QC level was prepared in six folds of which five were analyzed. 
The extracting solution consisted of cyanoimipramine 0.03 mg/L in a mixture of methanol and water 
(9:1, v/v). An 8 mm diameter disc was punched out from the DBS and was then transferred to an 1.5 mL 
Eppendorf tube where 300 µL of extracting solution was added. The extraction was accelerated by 60 
minutes of sonication. After sonication 200 µL of the extract was transferred to a polypropylene vial 
and 5 µL was injected into the LC-MS/MS system.
equipment and conditions
All samples were analyzed on a Thermo Fisher Scientific TSQ Quantum Discovery (Waltham, US) tri-
ple quadrupole LC-MS/MS with a Thermo Surveyor MS pump and a surveyor plus autosampler with a 
set temperature of +20ºC. Analyses were performed on a 50 mm x 2.1 mm HyPurity C18 5-µm analytical 
column (Interscience Breda, the Netherlands). The mobile phase at flow rate of 0.3 mL/min consisted 
of purified water, acetonitrile and an aqueous buffer (containing ammonium acetate 10 g/L, acetic acid 
35 mg/L and trifluoracetic anhydride 2 mL/L water). The buffer was maintained constant at 5% during 
the gradient (Table 1). 
The Thermo TSQ Quantum Discovery mass selective detector was used in positive ion mode and 
performed selected reaction monitoring as scanning mode. The mass parameters of m/z 402.0 - 358.2 
(collision energy 19 eV) and m/z 306.0 - 218.0 (collision energy 39 eV) were measured with scan width 
of 0.5 m/z for MFX and cyanoimipramine detection. Ion spray voltage, sheath gas pressure, auxiliary 
gas pressure and capillary temperature were set at 3500 V, 35 arb (arbitrary units), 5 arb and 3500C, 
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respectively. Peak height integration and quantification of the components were achieved with Xcali-
bur software version 1.4. SRI (Thermo Fisher Scientific, Waltham, US).
meThoD DeveloPmenT anD valiDaTion
method development 
To determine MFX in a DBS, a fixed diameter disc is punched out from DBS. Normally, it is assumed 
that blood volumes in different discs are equal. However, paper type, blood viscosity, that mostly 
relates to Hct, and Vb, were possible factors introducing analytical bias (13,14,19). As a consequence, we 
evaluated the variation in disc-weight and blood spreading with three types of paper including What-
man grade 3, Whatman 31ET CHR and Whatman 903. 
From each of six paper cards taken randomly, six blank paper discs were punched out and scaled to 
determine disc-weight variation. In addition, a precise blood volume of 10, 15, 20, 25, 30, 35, 40, 45, 50, 
55 and 60 µL with a Hct of 20, 35 and 50% was pipetted on the paper in 6 fold. From both sides of the 
blood spots, images were taken using a Nikkon D60 camera. Areas of blood spots were measured 
by image analysis using ImageJ® software (version 1.42q). The Vest was calculated using the equation: 
Vest = (1/4).p.d
2.Vb/SDBS (1)
In Eq. (1), d is diameter of the punch (8 mm); Vb and SDBS are blood volume and respective DBS area. For 
each type of paper, linear regression analysis was performed to estimate the effect of the two param-
eters, Hct and Vb, on the variation of Vest. The changes of Vest over the investigated range of Hct and Vb 
were calculated as ErrorHct = ΔHctbHct/V
–
est and ErrorVb = ΔVbbVb/V
–
est, respectively. In which, V
–
est is the average 
of Vest. ΔHct and ΔVb are the differences between the lowest and the highest values of Hct and Vb that 
were investigated, respectively; bHct and bVb are unstandardized regression coefficients of Hct and Vb. 
To develop the extraction method, different extracting solutions
including MeOH, ACN, water, the mixture of ACN:MeOH (16:84, v/v) and the mixtures of 
MeOH:water (10:90 and 20:80, v/v) were tested with a sonication time of 30min. The extracting solu-
tion was selected based on the visual signs and the chromatographic response of the extraction. With 
this extracting solution, the sonication time of 0, 10, 30, 60 and 100 min was evaluated and the optimal 
value was selected. The DBS at concentration of 2.5 mg/L was used in the method development.
method validation
The method was validated in terms of linearity, selectivity and specificity, accuracy, precision, dilution 
integrity, carry-over, process efficiency and stability (21). Validation was performed with a maximum 
tolerated bias and coefficient of variation (CV) of 20% for the LLOQ and 15% for the other validation 
concentrations. In addition, the influence of Hct and Vb were also evaluated.
Oneach of three consecutive days, a single calibration curve with eight concentration levels was ana-
lyzed. Calibration curves were then established using 1/x weighted linear regression. Peak height ratios 
of MFX and the internal standard were used to calculate concentrations. Inter and intra-day reproduc-
ibility was evaluated at LLOQ, LOW, MED, HIGH and OC levels. The extract at OC level was diluted 
ten times with the extract of a blank DBS and the analytical result was then multiplied by ten to correct 
for the dilution. Selectivity and specificity were evaluated by analyzing blank and LLOQ
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DBS samples prepared from five different batches of real human blood. The carry-over was estimated 
by injecting a blank sample five times after analyzing a HIGH-level sample. To calculate the process effi-
ciency, 10_L of blank and QC (LOW, MEDand HIGH) bloodwereused tomakea spot. The whole spot-
was punched out and extracted. Process efficiency, which was defined as matrix effect and recovery, 
was calculated from peak height responses of three solutions (A, B and C). Solution Awas the extract 
of 10_L-QC DBS in extracting solution. Solution B was the mixture of MFX stock solution and the 
extracting solution at concentrations equal to nominal values of solution A. Solution C was the extract 
of 10_L-blank DBS which was extracted by solution B. The matrix effect and recovery were determined 
as: matrix effect = (C–B)/B; recovery = A/C (14).
In addition, the matrix effect was also investigated by injecting the extracts of five DBS samples derived 
from finger pricks of MFX free volunteers while MFX and cyanoimipramine neat solution were post-
column infused (22).
The stability of processed samples after 24 and 48 hours stored in the auto-sampler was evaluated 
by re-injecting the extracts of previous days and calibrated by a freshly prepared calibration curve. 
Long-term stability was investigated for - 800C, room condition (250C and 50% of humidity), high tem-
perature (500C) and high humidity (~100% at room temperature) at 2 weeks and 4 weeks after DBS 
preparation. High humidity environment was created by storing DBS in a sealed plastic bag with wet 
tissues without contacting with DBS paper and monitored by a hygrometer. 
influence of hct and vb 
Tuberculosis patients have a relatively low Hct value of approximately 35 ± 6 % (23). For this reason, Hct 
values of 20, 25, 30, 35, 40, 45 and 50 % were evaluated using the same experiment described in Section 
2.4.1. A linear regression equation between Vest and Hct was constructed. Furthermore, the QC level of 
LOW, MED and HIGH at each Hct value were prepared, analyzed and calibrated by calibration samples 
with a Hct of 35 %. The result was then corrected by the following equation:
Ccorrected = Cobserved
Vstd
Vstd + b × (Hct – 35)
(2)
C corrected is the concentration after correcting for Hct; C observed is the concentration before correcting 
for Hct; Vstd is theVest at standardized Hct (35%); Hct is the Hct of corrected sample; b is the regression 
coefficient between Vest (mL) and Hct(%) 
Blood volumes of 30, 50 and 100 µL were used to make different DBS sizes. Discs were punched out 
from the central part of the DBS and analyzed in five fold. Calibration samples with a blood volume of 
50 µL were used to calculate the influence of Vb.
Clinical validation
The samples for clinical validation were taken from tuberculosis patients who received MFX 400 mg 
once daily orally as part of their treatment .The study protocol was approved by the local institutional 
ethics committee. Written informed consent was obtained from the patients. Venous blood sampling 
with a volume of about 3 ml was performed by nurses before the intake of the drug and at 1, 2, 3, 4 and 
8 h after oral administration. At each sampling time, a venous DBS was prepared by pipetting 50 µL of 
the venous blood onto the paper. The remaining venous blood was centrifuged at 3000 rpm and the 
plasma was withdrawn and stored at - 200C until analysis. In addition, at the time of pre-dosing, 2 and 8 
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h post-dose, finger pricks were taken and blood was dropped directly on the paper to make the finger 
prick DBS. The DBS were left dried for at least 3 h  then stored in a sealed plastic bag at -800C before 
analysis. The DBS samples were analyzed using the developed method and the plasma samples were 
analyzed by the routine analytical method in our laboratory (12). The correlations between venous 
DBS, DBS from finger prick and plasma concentrations were evaluated by simple linear regression and 
Passing-Bablok regression with the help of Analyse-it® software.  
resulTs 
method development
The evaluation of the different types of filter paper showed that disc weight relates to the paper’s 
thickness and its matrix. The variation in disc weight may contribute to the variation of Vest and sub-
sequently to the analytical result. Among the three types of paper tested the Whatman 31ET CHR 
showed the smallest variation in disc weight with a CV of 2.3% (Table 2).
With the assumption that blood equally spreads from the centre to peripheral of the DBS, Vest appar-
ently represents blood volume in a punched disc. Linear regression analysis showed that Hct and Vb 
highly contributed to the variation of Vest but was not equal among different types of paper. Whatman 
31ET CHR showed the highest R2 of 0.89 which means 89% of variation in Vest can be explained by the 
regression model for this type of paper. Furthermore, the effect of the Vb was of no significant influ-
ence (bVb =0.03, p- 0.246) suggesting that blood equally spreads on this paper regardless the size of 
DBS. In contrast, Hct is an important predictor which explains 88% (equal to b2Hct) of total variation of 
the Vest. If the results are corrected for Hct, the accuracy of the DBS method can be improved. For the 
other two types of paper the lower R2 value suggested that the variation in Vest is less explained by the 
Hct and Vb. In addition, the contributions of these parameters are not unique because bHct and bVb vary 
among different paper types (Table 2). 
The difference in Hct ranged from 20 to 50%. This produced an ErrorHct of 12.8% with Whatman N03, 
22.5% with Whatman 31ETCHR and up to 26.8% with Whatman 903. With Whatman 31ET CHR the 
ErrorVb was only 0.9% and this suggests the bias was not explained by Vb. However, with Whatman N03, 
the bias caused by Vb can reach 9.8%. The Whatman 31ET CHR showed a high correlation between the 
bias of Vest and Hct. Based upon these results the Whatman 31ET CHR was selected for the method 
development.
The extract in water was dark and not suitable for injecting into the LC-MS/MS system. We did not 
intend to develop another step to clean this extract because it required a more complicated proce-
dure. In addition, MFX appeared to be poorly extracted by ACN or the mixture of ACN:MeOH (16:84 
v/v) because a very low response was observed. The extract in MeOH was clear and produced a high 
chromatographic response. By adding 10 or 20% percent of water, the chromatographic response was 
improved. However, with 20% water, the extract became darker and therefore the mixture of 10% 
MeOH was selected. During the optimization of the extraction peak height responses increased with 
increasing sonication time. The maximum extraction performance was achieved at 60 minutes, where 
no significant difference was observed between 60 and 100 min (p - 0.43) (Fig. 1). Therefore, 60 min of 




No interfering peaks at the retention time of MFX and cyanoimipramine were observed in the chro-
matograms of 5 blank blood DBS samples. The responses of blank DBS samples were lower than 4% of 
those of the LLOQ DBS. These results showed that the method is selective and specific (Fig. 2).
linearity, accuracy and precision
Calibration regression lines (n=3) were linear in the range of 0.05 - 6 mg/L with correlation coefficients 
(R2) of 0.9986 ± 0.0015. The attained regression equation is: 
y = 0.1376 × (SD – 0.0156 × x + 0.00026 × (SD – 0.0014)
The results of inter and intra-day reproducibility, with respect to bias and precision were within 
accepted range for all QC levels, with a maximum bias of  -8.1% and a maximum CV of 8.7%. The maxi-
mum bias and CV of the OC samples after correcting for the dilution were -11.1% and 5.8%, respectively 
(Table 3).
During method development, carry-over was observed and re-injections of blank samples for at least 
4 times were needed to totally eliminate the carry-over effect. Consequently, 5 injections of blank 
sample were used after a HIGH level sample to resolve carry-over during validation.
recovery 
High recoveries of 84.5%, 85.1% and 92.6% for QC LOW, MED and HIGH were achieved and no signifi-
cant matrix effect was observed (Table 4). Furthermore, no significant ion suppression or ion enhance-
ment visually presented at the retention time of MFX (1.5 min.) or cyanoimipramine (2.0 min.) during 
ion suppression testing with post-column infusion (Fig. 3). 
stability 
The stability of processed samples in the auto-sampler was evaluated at 24 and 48 hours and complied 
with the validation criteria. For long-term stability, the DBS samples were stable at room conditions 
for 2 and 4 weeks. However, high humidity and high temperature significantly accelerated the degrada-
tion of MFX in DBS as the MFX amounts decreased up to -33.5% bias (Table 5). This indicates that the 
samples should not be exposed to high temperatures and extremely high humidity.
influence of hct and vb
The regression equation between Vest and Hct was:
Vest = 19.98 + 0.1398 × (Hct – 35)  (R
2=0.81)
From this result, Vstd of 19.98 and b of 0.1398 were applied to Eq. (2). Extreme Hct percentages showed 
high analytical biases before correcting. The difference of uncorrected concentrations between low-
est and highest Hct was approximately 40%. After correcting for Hct, the biases were lowered and fell 
within the accepted range of 15% (Fig. 4).
The Vb showed to have an effect on the concentration by less than 15% bias. The Vb showed to be 
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directly proportional to the concentration of the DBS. Even though the volume of the DBS has a minor 
effect on the concentration of the punched area of the DBS, it does affect the accuracy of the analysis 
within validation requirements (Fig. 5). 
Clinical validation
For clinical validation, the plasma, venous DBS and DBS from finger prick samples were taken from 6 
tuberculosis patients with hematocrit values of 26, 37, 33, 41, 35 and 38%. The simple linear regression 
showed excellent correlations between the plasma level and the DBS level: finger prick DBS, R2- 0.966 
(n - 18); venous DBS, R2 - 0.973 (n - 36). Using a Passing Bablok regression, the obtained slopes of regres-
sion lines between DBS and plasma concentrations was significantly higher than 1  (95% CI: finger prick 
DBS, 1.32 - 1.77; venous DBS, 1.50 - 1.66), and thus shows systemic differences between DBS and plasma 
concentrations (Fig. 6). A comparable result between finger prick DBS and venous DBS concentrations 
was observed: y - 1.01 x - 0.05 (95% CI slope: 0.92 to 1.11 and intercept: -0.23 to 0.01).
DisCussion
We developed a method of analysis for routine monitoring of MFX using dried blood spot sampling. 
Our method was based on punching and extracting a part of the collected blood spot using LC/MS/
MS. Validation was performed according to the guidelines for bioanalytical method. Effect of Hct and 
Vb were evaluated as part of this validation. The method is suitable for clinical pharmacokinetic studies 
and routine monitoring of MFX in daily practice. To the best of our knowledge this is the first described 
validation using DBS for MFX.
The Hct value and blood volume showed to have a relation with the size of blood spot. Blood with 
a high Hct shows an increased viscosity resulting in a smaller bloodspot. This factor needs to be 
addressed if the blood is not obtained with a volumetric capillary and only part of the spot is extracted 
and analyzed. However, sampling with a finger prick without volumetric capillary is easier and cheaper 
and can therefore be preferred in case of sampling in remote rural areas. The impact of Hct and Vb on 
the accuracy of DBS analysis should be emphasised during method validation. Our results showed 
that with a Hct range from 20 to 50%, a significant difference of 22.5% in Vest was observed and there-
fore results should be corrected for Hct value. The correction can help to reduce the bias but seems 
not to totally eliminate it. The remaining small bias may be the result of other factors such as chro-
matographic effect in which the higher Hct, the higher concentration of MFX in the central part of 
DBS (13,14). Wilhelm et. al. concluded that Hct ranged from 20 to 70% produced no significant bias of 
cyclosporin A concentration in DBS (15). Nevertheless, even though all biases were less than 15%, Hct 
of 20 and 70% seemed to produce a higher bias. In the clinical application of DBS, Marca et. al. sug-
gested that ignoring the impact of Hct could lead to a serious error especially if Hct levels not within 
the normal range (20). 
In case of sampling in remote rural areas, patients’ Hct values are not always available and in that case 
analytical bias caused by Hct seems unavoidable. However, as TB patients have a mean Hct value of 
35% and our method is calibrated on this point, the resulting difference on the concentration of MFX 
is generally small.   
In a clinical setting, it is difficult to control the size of the DBS without using a volumetric device. The 
effect of the size of the DBS on the bias of the result appeared to have less impact than the effect of 
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the Hct. The concentration of the DBS showed to be directly proportional to the blood volume it was 
created with. Although the volume of the bloodspot showed to be of influence, the differences were 
well within 15% bias (Fig. 5). Because the discs were punched out from the central part of the DBS, the 
possible reason could be the chromatographic effect of the paper in which MFX distributed more in 
the central and less at the peripheral part. This experiment proved that it is best to create bloodspots 
that show low variation in volume. On the other hand variation in volumes of 30-100 µL between 
patient blood spots will still be within validation requirements. 
An ion enhancement caused by ethylene diamine tetraacetic acid (EDTA) on MFX analysis was 
reported earlier (12). We also experienced ion enhancement with DBS prepared from fresh frozen 
plasma that contained citrate as anticoagulant. For that reason, we selected serum to prepare DBS in 
which a matrix effect of less than 15% was observed.
In the clinical validation, it appeared that the MFX concentration in DBS was significantly higher than 
in plasma. This can be explained by the unequal distribution of MFX between plasma and blood cells 
caused by a difference in binding capacity to plasma proteins and blood cells (24). The slope of the 
regression lines of 1.49 (95% CI: 1.32-1.77) for finger blood/plasma ratio and 1.59 (95% CI: 1.50 to 1.66) for 
venous blood/plasma ratio showed a higher concentrations in blood than in plasma. Despite these dif-
ferences, excellent regression correlations were observed. The ratio can be used to translate the DBS 
concentration into a plasma concentration. Comparable MFX concentrations between DBS from fin-
ger prick and veninpuncture were observed and thus suggested a similar MFX concentration between 
the venous and the finger capillary blood. This result also confirmed that the DBS sampling from the 
finger prick blood without a volumetric device was as reliable as using pipette. Although the free drug 
concentration of MFX cannot be calculated based on a DBS result, it still enables the attending physi-
cian to make clinical decisions on dosing MFX in TB patients. 
ConClusion
A rapid and fully validated LC-MS/MS method was developed for determining MFX in DBS. Vb is of 
minor influence compared to Hct value on the analytical result. MFX concentrations obtained with 
DBS are significantly higher than the plasma concentrations because of the blood/plasma ratio but 
show a good correlation. As MFX is stable in DBS at room conditions for at least 4 weeks, the method 
can facilitate pharmacokinetic studies and TDM of this drug in remote rural areas.
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Figure 1. Influence of sonication time on the response of DBS extract  (n = 5);
Result was presented as mean ± SD
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Figure 2. Represent chromatogram 
Chromatogram of cyanoimipramin (a) and moxifloxacin (b) in a blank DBS extracted by blank extracting solvent (A); in a blank 
DBS (B), a LLOQ DBS (MFX - 0.05 mg/L) (C) and a patient finger prick DBS (MFX - 1.49 mg/L) (D) extracted by extracting solvent 
with internal standard (cyanoimipraimin = 0.3 mg/L).
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Figure 4. Influence of Hct on analytical result and the correction (n = 5)
Before correction for Hct: (a); after correction for Hct: (b)
LOW: opened square, dash line; MED: closed triangles dot line; HIGH: closed circles, solid line,
Figure 5. Influence of blood volume on analytical result (n = 5)
LOW: opened square, dash line; MED: closed triangles dot line; HIGH: closed circles, solid line
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Figure 6. Correlation between MFX concentration in venous/finger prick DBS and plasma 
Correlation between venous DBS and plasma concentration (cross): Passing Bablok regression line (dot line, n -36), y = 1.59x - 0.04 
(95% CI slope: 1.50 - 1.66, intercept: -0.15 - 0.03); simple linear regression coefficient R2= 0.973. Correlation between finger prick 
DBS and plasma concentrations (closed circles): Passing Bablok regression line (dash line, n- 18), y = 1.49 x - 0.05 (95% CI slope: 1.32 
- 1.77, intercept: -0.30 - 0.06; Simple linear regression coefficient R2= 0.966.
Table 1. Solvent gradient program
Time (min) buffer (%) Water (%) Acetonitrile (%)
0 5 95 0
0.5 5 35 60
1.6 5 35 60
1.61 5 0 95
2.9 5 0 95
2.91 5 95 0
3.5 5 95 0
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Table 2. Variability in disc weight and the effect of Hct, Vb on Vest among 3 types of paper
Paper Disc weight (mg) Effect of Hct and Vb on Vest
Mean CV (%) Mean (SD) bHct bVb R
2 ErrorHct ErrorVb
N0 3 9.10 4.1 15.87 (1.22) 0.68 * 0.41 * 0.62 12.8% 9.8%
903 9.32 3.2 18.95 (2.48) 0.84 * 0.13 * 0.72 26.8% 5.2%
31ET CHR 9.59 2.3 19.95 (1.95) 0.94 * 0.03 0.89 22.5% 0.9%
Hct was centralized at 35% and Vb was centralized at 35 (mL) 
bHct, bVb: standardised regression coefficient of Hct and Vb
R2: total correlation coefficients of the model.
*: p <0.001
Table 3. Accuracy and precision results (n=5)
QC level (Nominal 
conc.) (mg/L)
Mean conc. (mg/L) Precision (CV %) Accuracy (bias %)
Day1 LLOQ (0.05) 0.053 6.8 5.8
LOW (0.15) 0.146 8.7 -2.6
MED (2.50) 2.572 2.4 2.9
HIGH (5.00) 5.244 1.7 4.9
OC (10.00) 10.343 5.5 3.4
Day2 LLOQ (0.05) 0.051 4.9 2.8
LOW (0.15) 0.138 3.5 -8.1
MED (2.50) 2.360 3.3 -5.6
HIGH (5.00) 4.705 2.4 -5.9
OC (10.00) 8.892 2.3 -11.1
Day3 LLOQ (0.05) 0.050 5.4 0.3
LOW (0.15) 0.153 2.8 2.2
MED (2.50) 2.388 5.5 -4.5
HIGH (5.00) 4.968 3.2 -0.6
OC (10.00) 8.955 5.8 -10.4
Inter-day LLOQ (0.05) 0.051 5.8 3.0
LOW (0.15) 0.146 6.9 -2.8
MED (2.50) 2.440 5.4 -2.4
HIGH (5.00) 4.972 5.1 -0.6
OC (10.00) 9.397 8.7 -6.0
LLOQ: lower limit of quantification; MED: medium; OC: over the calibration curve
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LOW (0.15) A 0.020 6.0 - 3.4 84.5
B 0.024 3.7
C 0.024 3.8
MED (2.50) A 0.335 2.5 -11.9 85.1
B 0.446 5.1
C 0.393 1.8
HIGH (5.00) A 0.676 3.3 -5.1 92.6
B 0.769 2.0
C 0.730 1.2
A, B and C = response of solution A, B and C 













CV (%) Bias (%)
- 800C LOW (0.15) 0.156 3.5 4.1 0.161 4.3 7.4
HIGH (5.00) 4,886 1.8 -2.3 5.324 4.9 6.5
Normal LOW (0.15) 0.158 4.2 5.5 0.158 6.0 5.4
HIGH (5.00) 4,660 2.9 -6.8 5.231 6.0 4.6
500C LOW (0.15) 0.124 5.8 -17.1 0.112 4.5 -25.4
HIGH (5.00) 3,869 1.4 -22.6 3.503 6.2 -29.9
Humidity LOW (0.15) 0.117 31.9 -21.7 0.124 17.1 -17.4
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absTraCT
Clarithromycin and rifampicin are used for the treatment of mycobacteria. Pharmacokinetic 
drug interaction is possibly due to the influence of the two drugs on the liver enzymes. using 
a hypurity aquastar C18 column (50 mm x 2.1 mm x 5 mm) for liquid chromatography includ-
ing a polar end-capped phase for the determination of clarithromycin, rifampicin and their 
metabolites together  in plasma using lC-ms/ms resulted in a substantial carry-over. as 
a consequence, the throughput of the method is not assured. using a step by step trou-
bleshooting procedure, such carry-over was found originating from column memory effect. 
With the use of another type of C18 column, the carry-over is eliminated. Due to the absence 
of carry-over, the analytical concentration ranges are extended and are therefore more 
appropriate for the analysis of patient samples. The method was re-validated for linearity, 
reproducibility and dilution integrity.
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inTroDuCTion
The combination of rifampicin (RIF) and clarithromycin (CLR) can be used to improve the treatment 
outcome and prevent the resistance of Mycobacteria. It is well reported that RIF is a strong liver 
enzymes inductor while CLR is an inhibitor. Several small studies suggested that RIF may reduce the 
CLR plasma concentration while CLR, on the other hand, elevates the RIF plasma level (1,2). For that 
reason, therapeutic drug monitoring of these substances may help to assure adequate drug exposure. 
Furthermore, the metabolism of RIF and CLR by cytochrome P450 results in active metabolites includ-
ing 25-desacetylrifampicin (Dac-RIF) and 14-hydroxyclarithromycin (14OH-CLR), respectively (3,4). 
The analysis of these substances is therefore recommended, but is seldom implemented in analytical 
methods (5,6). Osward et. al. developed a method for simultaneous determination of CLR and RIF and 
their metabolites but not in human plasma (6). The LC-MS/MS method published by van de Velde 
et. al. could simultaneously determine CLR, RIF and their metabolites in human plasma (5). In this 
method, the authors reported a persistent carry-over in the analysis of RIF and Dac-RIF which required 
five blank injections to eliminate if high standard or quality control sample was eluted. Because of 
the carry-over, the LLOQ for RIF and Dac-RIF was 0.2mg/L which is relatively high in comparison with 
low plasma trough level of these substances (1,7,8). In addition, if the concentration of RIF or Dac-RIF 
is higher than the upper limit of quantification (ULOQ: 5 mg/L), the sample needs to be diluted, and 
re-analyzed. It is noticeable that the peak concentration of RIF in plasma is normally higher than 5 mg/L 
(1,7,8). Therefore, the carry-over should be eliminated to increase the throughput of this analytical 
method in routine practice.
Contamination and carry-over are common encountered problems with LC-MS/MS analyses (9). First, 
the contamination may occur during the sample preparation which is normally related to the extrac-
tion procedure. Second, contamination can be generated due to the auto-sampler carry-over. Third, 
due to secondary interactions in the column a column memory effect may be induced. (10). Dealing 
with the carry-over requires the combination of systemic and logical investigation (9).
Therefore the aim of the study was to detect and eliminate the carry-over and make the method of 
analysis more suitable for routine analysis.
meThoDs 
Troubleshooting the carry-over
An effort to detect and eliminate the carry-over from the auto-sampler and column was tried. A more 
thorough auto-sampler (e.g. needle, needle tube and needle seat) flushing and washing procedures using 
different solvents (acetonitrile, isopropanol and their mixtures) were tested. If the auto-sampler flush-
ing and washing provided no improvement, the carry-over from the column was examined by using a 
“duplicated” solvent gradient. The previous solvent gradient was performed in 3.5 minutes as follows: 0-2 
minutes: ACN from 0 to 95%, water from 95% to 0%; 2-3 minutes:  ACN 95% and water 0%; 3-3.1 minutes: 
decrease ACN to 0% and keep eluting with water 95% until 3.6 minutes. The aqueous buffer (ammonium 
acetate 10 g/L, acetic acid 35 mg/L and trifluoroacetic anhydride 2 mg/L, pH 3.5) was kept at 5% during 
the gradient (5). The “duplicated” solvent gradient consisted of two gradients, as described before, com-
bined in one analysis. In this way an injection is eluted by the first gradient, while the second gradient is 
performed without sample injection (Figure). A high concentration sample at ULOQ level (upper limit of 
quantification; RIF: 30mg/L; Dac-RIF, CLR and 14OH-CLR: 10mg/L) was injected and eluted.
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To estimate the carry-over effect, 3 samples including a LLOQ (lower limit of quantification RIF; Dac-
RIF: 0.15mg/L; CLR, 14OH-CLR: 0.05 mg/L), a ULOQ and a blank sample were subsequently injected 
into the LC-MS/MS system. The carry-over was defined as the percentage of responses from the blank 
sample to the respective LLOQ sample.
method validation
Two different stock solutions for the calibration and quality control samples were prepared in 
methanol:water (1:1v/v) containing the following concentrations: RIF: 600 mg/L; Dac-RIF, CLR, and 
14-OH-CLR: 200 mg/L. Subsequently, the stock solutions were diluted ten times to produce working 
stock solutions. All stock solutions were stored at 40C. Calibration samples (Table 1) and quality control 
samples at levels of LLOQ, LOW, MED, HIGH and over the calibration curve (OC) (Table 2) were pre-
pared by mixing appropriate amounts of stock solutions or working stock solutions with blank human 
plasma (received from the Hematology department of UMCG). The added volume of stock solution 
was less than 5% of the total sample volume.
A plasma volume of 10 µl was transferred into a glass vial with 750 µl of protein precipitation solution, 
which consists of cyanoimipramine as internal standard in ACN:MeOH (21:4 v/v), The sample was vor-
texed for 1 minute and then stored for 30 minutes at -200C to accelerate the protein precipitation. After 
1 minute of vortexing and 5 minutes of centrifuging at 11,000 rpm, 5 µl of supernatant was injected 
onto the Hypurity C18 column (50 mm x 2.1 mm x 5 mm). For the detection of the analytes a Thermo 
Fisher triple Quadrupole detector was used. The MS/MS conditions were defined in the previously 
published method of de Velde et al. (5).
Each day of a three day validation, a calibration curve and a set of quality control samples were ana-
lyzed. Linear regression weighted by 1/X2 was used to construct the calibration curve. For determina-
tion of accuracy, precision, and dilution integrity, quality control samples were prepared and measured 
in 5-fold. Within-run, between-run, and overall bias and coefficient of variation (CV) were calculated 
using a 1-way ANOVA. Maximum tolerated bias and CV was 20% for the LLOQ and 15% for the other 
validation concentrations (11).
resulTs anD DisCussion
Trouble shooting the carry-over of the analysis method for rif and Dac-rif
The carry-over may come from the auto-sampler, the switching system or the LC column (10). No 
improvement in terms of carry-over was attained by using different kinds of flushing and washing pro-
grams and solvents to clean the auto-sampler system. Interestingly, the chromatography of “dupli-
cated” solvent gradient presented a significant column memory effect of RIF and Dac-RIF (Figure). 
Because the “duplicated” solvent gradient by-passes the auto-sampler and the switching system 
during the elution period, it is suggested that the persisting “carry-over” in the previously published 
method resulted from column memory effect.
To eliminate the column memory effect, several gradients were tested using longer eluting periods. 
Despite of these efforts the memory effect was persistent and the carry-over peaks maintained at 
about 2% and 4% of the main peaks for Dac-RIF and RIF, respectively. With such high carry-over, the 
analytical bias of low concentration sample could be dramatically influenced if the previous sample 
is at high concentration. Injecting several blank samples gradually reduced the carry-over peak yet 
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increased the time of analysis. Extending the elution up to 6 minutes and increasing the acetonitrile 
elution phase reduced the carry-over up to 0.7% and 0.2% for RIF and Dac-RIF, respectively. However, 
short runtimes were important to ensure a high throughput of a routine analysis. Moreover, increasing 
the ULOQ of the original method was preferred for RIF and Dac-RIF to minimize re-analysis of over the 
curve patient samples. For this purpose, carry-over should be further minimized and therefore another 
approach should be introduced.
The method published by de Velde et. al. used a Hypurity Aquastar C18 column (50 mm x 2.1 mm x 
5 mcm) for liquid chromatography (5). The polar end-capped phase added in this column might be 
the explanation for the observed carry-over. RIF and Dac-Rif may interact with the stationary phase 
result in the column memory effect. For that reason a Hypurity C18 column without polar end-capped 
phase was tested. Using this column, the carry-over effect observed in an analysis of the first blank 
sample followed after an ULOQ was dramatically reduced to less than 0.08% for all four substances. In 
addition, with some adjustment of the solvent gradient program, the elution time was shortened to 3 
minutes while the peak shapes remained good and the carry-over was excluded. With this finding, the 
linear analytical range of all four substances could be extended: RIF: 0.15 mg/L – 30 mg/L; Dac-RIF: 0.15 
mg/L – 10 mg/L; CLR and 14OH-CLR: 0.05 mg/L – 10mg/L.
method validation
The method showed good linearity for all four analyzed substances. The equation of the calibration 
curves and the correlation coefficients are presented in Table 1. In each assay, the deviations of the cali-
bration samples to the linear calibration curves were less than 20% for the lowest concentration and 
15% for the other concentrations. It is noticeable that the method was validated with larger analytical 
ranges than the method published by de Velde et. al. On the one hand, no blank injection was needed 
to exclude the carry-over. On the other hand, the higher ULOQ levels for RIF and Dac-RIF assure the 
analysis of higher concentrations without the need of diluting and re-analysis of the samples. As a con-
sequence, the new method is more practical for the analysis of real patient plasma samples.
The reproducibility presented as bias and CV were according to the FDA guidelines (11). All the bias 
and CV values were less than 20% at LLOQ level and less than 15% at the other QC levels. Diluting the 
over curve concentration sample influenced neither the accuracy nor the precision of the validated 
method (Table 2).
ConClusions
With the adapted method the carry-over is eliminated and blank sample injections to reduce carry-
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Figure. 
Chromatogram of the elution of an ULOQ sample using a “duplicated” solvent gradient; (I): 25-desacetylrifampicin; (II): 
Rifampicin; (III): the “duplicated” gradient; (a): peaks of the first elution period; (b): Peaks due to the memory effect
Table 1. The concentrations and the inter-assay variation of the calibration curves (n=3)
Component Calibration concentration (mg/L) Slope ± SD Intercept ± SD Correlation coefficient  (R)
CLR 0.05, 0.15, 0.5, 1.0, 3.0, 5.0, 8.0, 10.0 0.421 ± 0.0065 0.0008 ± 0.0064 0.9974
14OH-CLR 0.05, 0.15, 0.5, 1.0, 3.0, 5.0, 8.0, 10.0 0.269 ± 0.0031 -0.0020 ± 00029 0.9985
RIF 0.15, 0.45, 1.5, 3.0, 9.0, 15.0, 24.0, 30.0 0.449 ± 0.0081 -0.014 ± 0.0032 0.9971
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absTraCT
introduction: rifampicin (rif) and clarithromycin (Clr) are common drugs for the treat-
ment of infectious like Mycobacterium tuberculosis and Mycobacterium ulcerans. The intensive 
and long treatment confront sub-therapeutic or toxicity because of pharmacokinetic vari-
ation, drug-drug interaction or non adherence to the treatment. Therapeutic drugs moni-
toring (TDm) is used to ensure efficacy and to avoid toxicity. With the application of dried 
blood spot (Dbs), the TDm may be feasible in rural area. 
methods: an investigation focused on the interaction between rif and the endogenous 
components of the Dbs. a rapid analytical method was developed and validated to quantify 
rif and Clr and their active metabolites desacetyl rifampicin (Dac-rif) and 14 hydroxy clar-
ythromcin (14oh-Clr) in Dbs samples. The method was clinically validated on tuberculosis 
patient by comparing Dbs concentration and plasma concentration
results: The interaction between rif with Dbs matrix was competed with the present of 
ethylenediaminetetraacetic acid and deferoxamine, complexing agent. The competition was 
applied to develop a simple and fast method for simultaneous quantification of rif, Clr and 
their metabolites in Dbs specimen. high stability was observed as all four substances were 
stable at room temperature for two months. high correlation between plasma and Dbs con-
centration rif (r2=0.9067) Clr (r2=0.9785) and 14oh-Clr (r2=0.9421) was observed.
Conclusion: The validated method is applicable for TDm of rif and Clr and their active 
metabolites.
Chapter 6b
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inTroDuCTion
Rifampicin (RIF) and clarithromycin (CLR) are two drugs used for the treatment Mycobacterial infec-
tions. According to the tuberculosis (TB) treatment guideline of World Health Organization, RIF is 
the back bone of the first line anti-TB drugs in the treatment of Mycobacterium tuberculosis. CLR is 
indicated for treatment of multidrug resistant (MDR) TB. In combination, RIF and CLR showed high 
efficacy for the treatment of Mycobacterial ulcerans which is the organism causing Buruli Ulcer disease 
(1). RIF display’s large pharmacokinetic variability that may result in subtherapeutic drug exposure 
(2,3). It is well known that RIF is a liver enzymes inductor while CLR is an inhibitor. Several studies 
suggested that RIF reduced the CLR plasma concentration while CLR, on the other hand, increased 
the RIF plasma level (4,5). Furthermore, the metabolism of RIF and CLR by cytochrome P450 results 
in active metabolites including 25-desacetylrifampicin (Dac-RIF) and 14-hydroxyclarithromycin (14OH-
CLR), respectively (6-8). To assure adequate drug, exposure by therapeutic drug monitoring (TDM) of 
these drugs may help to improve the treatment outcome. 
The common endemic areas for TB or Buruli Ulcer disease often have limited resource.  Conven-
tional plasma sampling is often not feasible due to lack of equipment or cooled transportation (9). 
Dried blood spot (DBS) sampling has many advantages such as prolonged sample stability, lower risk 
of infections and transport at room temperature (9,10). These advantages may facilitate the applica-
tion and implementation of TDM of drugs even in resource limited areas. Methods of analysis for the 
determination of RIF or CLR in the biological fluids using high performance liquid chromatography 
(HPLC), liquid chromatography tandem mass spectrometry (LC-MS/MS) have been reported earlier 
(11,12), including simultaneous determination of rifampicin and clarithromycin (14,15). Only report 
described the development of an analytical method to determine RIF in DBS using HPLC (13). However, 
the extraction method is complex showing low sensitivity and do not account for determination of 
DAc-RIF. The application of LC-MS/MS with high selectivity and sensitivity can help to deal with these 
limitations. The development of a dried blood spot analysis method is confronted with challenges 
that need to be solved during method development and validation. DBS samples can be extracted 
by hydrophilic or hydrophobic organic solvents (16-18). Aqueous extraction has a drawback that it 
extracted endogenous components from the DBS as well (19). The endogenous components in the 
blood may cause unexpected interactions or matrix effects during the analysis (21). The application of 
ethylenediaminetetraacetic acid (EDTA) to precipitate endogenous components has been successfully 
applied before (20). Another complication compared to plasma analysis is that RIF can form chelate 
complexes with ferric ions or can bind with hemes which are potential presented in the extract of 
dried blood spot (20,22). In addition to the standard validation criteria, the influence of hematocrit 
value and blood spot volume should be assessed during the method validation (9,10,23). Furthermore, 
before DBS is implemented in daily routine, the correlation between RIF DBS and plasma concentra-
tions should be demonstrated (9,10,23). The aim of this study is to develop a rapid LC-MS/MS method 
for determination of RIF, CLR and their metabolites in DBS which is suitable for TDM clinical pharma-
cokinetic studies in rural areas.
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maTerials anD meThoDs
Chemical, reagent and disposables
Clarithromycin (C38H69NO13) and 14-hydroxyclarithromycin (C38H69NO14) were provided by Abbott 
(IL, USA). Rifampicin (C43H58N4O12) and 25-desacetylrifampicin (C41H56N4O11) were provided by Sanofi-
Aventis (Frankfurt, Germany). The 2H8-Rifampicin and cyanoimipramine were supplied by Brunschwig 
Chemie (Amsterdam, The Netherlands) and by Roche (Woerden, The Netherlands), respectively. 
Water and acetonitrile of ultra LC/MS grade were supplied by Biosolve (Valkenswaard, The Neth-
erlands). Disodium ethylenediaminetetraacetic acid (EDTA), ammonium acetate, acid acetic and 
trifluoroacetic anhydride were of analytical grade and purchased from VWR (Amsterdam, the Neth-
erlands).  Deferoxamine mesilate was attained from Novartis Pharma (Arnhem, the Netherlands). 
Pooled plasma and packed red blood cells were achieved from Department of Hematology, University 
Medical Center Groningen according to local regulations. The Whatman 31 ET CHR paper sheet was 
cut in to 4⩽6 cm paper cards and used for the preparation of calibration and quality control (QC) DBS 
and patient sampling.
sample preparation
Prepare the stock solutions 
Two separate stock solutions were prepared in water at a concentration of 600 mg/L for RIF and 
200mg/L for the other three analytes. These stock solutions were used to prepare the calibration 
curve and QC samples. For spiking low concentrations, the stock solutions were diluted with water 
to 25 mg/L. This ensures that the spiked volume of the stock solution could not exceed 5% of the total 
volume. The stock solutions were stored at 40C. 
Preparation of the Calibration Curve and QC in Blood 
The packed red blood cells (RBC) achieved from the hematology department contained a preservation 
solution. To completely remove the preserving solution the RBC were centrifuged at 4000 rpm for 
10 minutes and the upper layer was discarded. To wash the RBC, an equal volume of phosphate buff-
ered saline with pH 7.4 was added and mixed by a rotating mixer for 5 minutes. The RBC suspension 
was centrifuged and the upper layer was discarded. The RBC washing procedure was subsequently 
repeated twice with phosphate buffered saline and lastly with plasma. The RBC was mixed with plasma 
and stock solution to obtain calibration and QC blood at the desired hematocrit values. All the calibra-
tion and QC blood samples were prepared at the standardized hematocrit value of 35%. The concen-
trations of each component in the calibration and QC samples are presented in Table 1.
Prepare the DBS Samples 
The calibration and QC DBS samples were prepared by pipetting 50 µl of blood onto the paper card 
and left to dry for 3 hours at ambient temperature. DBS cards were stored separately in a sealed plastic 
bag with a desiccant sachet at -200C. 
DBS Extraction
The extracting solution consisted of 2H8-Rifampicin 0.25 mg/L (internal standard of RIF), cyanoimi-
pramine 0.05 mg/L (internal standard of DAc-RIF, CLR and 14OH-CLR), EDTA 1 g/L and deferoxamine 
2 g/L in water. A disc with a diameter of 8 mm was punched out from the central part of DBS and 
transferred to a 1.5 mL Eppendorf plastic tube. An extracting solution volume of 300 µL was added and 
the extraction was accelerated by sonication for 20 minutes. After extraction 200 µL of the extract 
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was transferred to a glass vial and a 600 µL of acetonitrile was added to precipitate the endogenous 
components in the extract. The sample was vortexed for 1 minute and centrifuged at 11000 rpm for 5 
minutes and 5µL of the supernatant was injected into the LC-MS/MS system.
equipment and Conditions
The LC-MS/MS system was consisted of a Surveyor® MS pump and a Surveyor plus® autosampler con-
nected with a Thermo Fisher Scientific TSQ Quantum Discovery, triple quadrupole mass spectrom-
etry (Waltham, US). The autosampler and column were set at a temperature of 200C.  The chroma-
tographic analysis was performed on a 50 mm×2.1 mm×5µm HyPurity C18 column and (Interscience 
Breda, the Netherlands). The analytes were eluted with a flow rate of 300 µl/minute using a solvent 
gradient as followed: 0 – 1 minute, ACN from 0% to 95%, water from 95% to 0%; 1-2.5 minute, ACN 
95% and water 0%; 2.5- 2.6 minute, decreased ACN to 0% and kept eluting by 95% water until 3.5 min-
utes. The aqueous buffer (ammonium acetate 10g/L, acetic acid 35mg/L and trifluoroacetic anhydride 
2mg/L) was kept at 5% during the gradient. 
The Thermo TSQ Quantum Discovery mass selective detector worked in positive ion mode and per-
formed selected reaction monitoring (SRM) at a scan width of 0.5m/z. The mass parameters for each 
analytes and the internal standards are presented in Table 1. The ion spray voltage, sheath gas pressure, 
auxiliary gas pressure and capillary temperature were set at 3500 V, 35 arb (arbitrary unit), 5 arb and 
3500C, respectively. The Xcalibur software version 1.4 SR1 was used for peak height integration and 
quantification (Thermo Fisher, Waltham, USA).
method development
The DBS at MED level was used for roughly evaluating the efficiency of different methods of extrac-
tion. Because the analytical method for simultaneous determination of the analytes in plasma has been 
successful validated, the DBS analytical method development was focused on the matrix effect and 
recovery (15). Extracting solvents including water, mixtures of 0%, 30% and 80% acetonitrile in metha-
nol were tested. The extraction was accelerated by a 60 minute of sonication at room temperature and 
the extract was injected into the LC-MS/MS. The matrix effect and recovery in the method develop-
ment were evaluated with the sample preparation in triplicate (23). Matrix effects, which may originate 
from the paper, the extraction solvent and the human blood matrix, were investigated. Similar extrac-
tion procedures using neat solution containing analytes in methanol were performed in triplicate for 
blank paper disc, 10µL of packed red blood cell, 10µL of plasma, 10µL of phosphate buffered saline. 
The DBS aqueous extraction suffers from endogenous matrix effects and therefore requires a cleaning 
process (9,19). A volume of 600 µL acetonitrile was added to precipitate 200 µL DBS aqueous extract 
containing EDTA and/or deferoxamine. The appropriate concentration of EDTA and deferoxamine in 
the extracting solution for precipitating the endogenous components was investigated. The extract-
ing solutions with EDTA and deferoxamine at concentrations of 2 g/L were used. The precipitation 
procedure was performed as described before. UV-VIS absorption spectra with a wavelength range of 
200-600nm was obtained from the varying supernatants using Varian UV-VIS spectrometry to indicate 
the cleanliness of these solutions. 
method validation 
The method was validated in accordance with the US Food and Drug Administration’s Guidance for 
Industrial Bioanalytical Method validation (24). The validated criteria included the selectivity, linear-
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ity, accuracy and precision, dilution integrity, carry-over, process efficiency and stability.  Besides, the 
influences of hematocrit and blood volume of DBS were evaluated as additional criteria that are rec-
ommended for DBS analysis (9,10,23). The validation was performed with maximum tolerated bias and 
coefficient of variation (CV) of 20% for the lower limit of quantification (LLOQ) and 15% for the other 
validated concentrations. 
Selectivity, specificity and carry-over 
The selectivity and specificity were evaluated by comparing the responses of the LLOQ and blank DBS 
samples prepared (9) from 5 batches of human blood. The average response of blank DBS samples was 
required to be within 20% of the average response of the LLOQ samples. The carry-over was assessed 
using the response ratio of a blank sample injected after a HIGH QC and LLOQ. The response was 
required to be less than 20% of the LLOQ QC.
Linearity, reproducibility and dilution integrity
On each of three consecutive validation days, a single calibration curve was analyzed to assess lin-
earity. The calibration curves were constructed using 1/x2 weighted linear regressions. The analytical 
responses, which were the peak height ratios between analyte and respective internal standard, were 
used for the quantification. Additionally, in each validation day, five QC´s of LLOQ, LOQ, MED, HIGH 
and OC (over the calibration curve) were analyzed in five folds to evaluate the intra-day and inter-day 
accuracy and precision and dilution integrity. The precipitated supernatant from OC samples were 
diluted 10 times with extract of a blank DBS before injection. Accuracy and the inter-day and intra-day 
precision was estimated using one-way analysis of variance (one-way ANOVA).
Matrix effect, complexing effect and recovery
The process efficiency was fully evaluated as the matrix effect, complexing effect and recovery at three 
QC levels of LOW, MED and HIGH. Different solutions A, B, C, D, E, F and G were prepared in five-
fold as presented in Table 2. To precisely calculate the theoretical concentration of the neat solution, 
a blood volume of 10µL was used to prepare the DBS in order to be able for punching the whole DBS 
for extraction.  The prepared solutions were sonicated in 20 minutes and 690 µL of acetonitrile was 
added to each sample. After vortexing for 1 minute and centrifuging at 11000 rpm in five minutes, the 
supernatant was transferred to a glass vial and injected into the LC-MS/MS. The influence of Fe (III) 
and DBS were estimated by assessing the peak height ratios of B/A and C/A, respectively. The recov-
ering effect of adding complexing agents calculated as E/D and F/D. Recovery and process efficiency 
were G/D and F/D, respectively. 
Effect of hematocrit and blood spot volume
Hematocrit and blood spot volume may affect the analytical result and therefore these parameters are 
evaluated. The effect of Hct was evaluated using QC blood at three Hct values of 20, 35, 50%. The effect 
of blood spot volume was assessed by preparing DBS with blood volumes of 30, 50 and 100 µL. At each 
Hct level and blood spot volume, three QC levels of LOW, MED and HIGH were analyzed in five-fold. 
The analytical results were corrected for their hematocrit value (19). The bias which is calculated as the 
difference between the analytical result and the nominal concentration (in percentage) present the 
effect of Hct and blood spot volume.
Stability
The stability of the analytes in DBS was tested with QC levels LOW and HIGH after storing at tem-
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peratures of 500C for 1, 3, 7 and 15 days, at 370C and ambient temperature for 10, 20 and 30 days and at 
room temperature for 7, 30 and 60 days. The samples were prepared and analyzed in fivefold and the 
analytical result was compared with their nominal concentration.
Clinical validation
Adult tuberculosis patients in the TB unit of the Beatrixoord hospital who received rifampicin or 
clarithromycin were eligible for clinical validation. The proposal was approved by medical ethical com-
mittee of University Medical Central Groningen. Informed consents were obtained from all participat-
ing patients. Three DBS samples at 0, 2 and 8 hours after dosing for clarithromycin or 1,2 and 4 hours 
after dosing for rifampicin were collected from each patient by a finger prick to create a bloodspot 
from a single drop on the paper cards. The DBS samples were then left dry at ambient temperature for 
3 hours and stored separately in a sealed plastic bag with a desiccant sachet at -200C until analysis. A 
venous blood sample was taken at the same time with DBS sampling using an EDTA vacutainer. After 
centrifuging for 5 minutes at 3000rpm, the plasma was obtained and stored at -200C before being rou-
tinely analyzed by a validated method (15). The correlation between DBS and plasma analytical results 
were assessed using ordinary least square regression. 
resulTs 
method development
The DBS extracting method was intensively investigated by testing various extracting solvents. With 
the use of methanol or its mixture with acetonitrile, a dramatic decrease in peak height of rifampicin 
was observed. The acetonitrile appeared to negatively influence the recovery. The acetonitrile propor-
tion up to 84% in methanol resulted in recovery of less than 3% for all four analytes (Table 3).
During method development it was observed that the rifampicin peak height was negatively influ-
enced by matrix effects of DBS and red blood cells. The same effect was observed if FeCl3 50mg/L was 
added to the neat solution. The propose assumption is that rifampicin may bind with components in 
the DBS matrix in which Fe3+ was suggested to be a potential factor (20). Therefore, the un-fragmented 
mass of RIF-Fe(III) (m/z= 879, collision energy = 0eV) was checked and a small peak at the identical 
retention time with rifampicin was observed. The efforts to adjust the chromatographic conditions or 
by adding complexing agents (i.e. EDTA and DFX) were however unsuccessful to recover the response 
of rifampicin. 
The aqueous extraction of DBS yield a dark red extract which is not suitable to directly inject into 
LC-MS/MS system. Using acetonitrile and methanol did not sufficiently precipitate the endogenous 
components in the extract. However, the use of an aqueous extracting solution containing EDTA can 
initiate the precipitation of endogenous components. With the EDTA concentration range from 0 to 
1.58 g/L, the precipitation was dependent on the EDTA concentration. As the concentration of EDTA 
increased, the amount of precipitating endogenous components in the DBS was increased and there-
fore the supernatant was cleaner. At EDTA concentration higher than 0.58 g/L, the precipitated extracts 
appeared to be totally colorless and UV-VIS spectra presented no significant absorbance peak (Figure 
1). Although the EDTA concentration of 0.58 g/L was sufficient to precipitate endogenous components 
in the DBS, the EDTA concentration of 1 g/L was used as between patient variability in blood character-
istics may occur. The precipitation of endogenous components from the aqueous extract of DBS using 
EDTA and acetonitrile was simple, rapid and can be applied to analysis method for other drugs also.
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Although the precipitated extraction was optically clean with the presence of EDTA, the peak height of 
rifampicin was still approximately 50% of the peak height of respective neat solution. It was recovered 
to approximately 100% after adding deferoxamine 1mg/L to the extracting solution. 
method validation
Selectivity, specificity and carry over
The mean response of the blank samples accounted for less than 4.6% of the response of LLOQ sam-
ples. In addition, all six batches of human blood showed no signal higher than 20% response of the 
LLOQ sample prepared from the same matrix. A corresponding chromatogram is presented in figure 
2. No carry-over was observed for all four analytes as the responses of the blank sample after injecting 
a HIGH QC sample were less than 20% response of LLOQ samples.
Linearity, reproducibility and dilution integrity
The method showed to be linear with correlation coefficients (r2) between the calibration curves of 
RIF, DAc-RIF, CLR and 14OH-CLR of 0.9953, 0.9971, 0.9987 and 0.9986, respectively. The linear model 
test based on ANOVA showed no significant lack of fit. The CV and bias (n=3) at each calibration level 
were all less than 15%. 
The reproducibility of the method was evaluated as the accuracy and the within day and between day 
precision. The accuracy and precision estimated by one-way ANOVA analysis were tolerated accord-
ing to the criteria of the FDA guidelines in which acceptable bias and CV are less than 20% for LLOQ 
and 15% for other validation concentrations (Table 3). 
The accuracy and precision results for the 10 times diluted OC samples were within the acceptance of 
FDA guidance and proved the dilution integrity of the method (Table 3). 
Matrix effect, complexing effect and recovery
There was a dramatic drop of the peak height of rifampicin in the presence of FeCl3 or DBS matrix. With 
the use of an extracting solution containing complexing agents, the effects of both matrices on the 
response of rifampicin were neutralized. The matrix effects of DBS with the presence of EDTA and DFA 
were 102%, 106% and 96% for the LOW, MED and HIGH levels of RIF respectively. The peak height of 
DAc-RIF showed a small increase with the use of the complexing agents. The matrix effects of CLR and 
14OH-CLR were of minor extent regardless the presence of the complex agents. A high recovery of 88% 
to 102% was achieved at three QC levels for CLR and 14OH-CLR. A lower recovery of RIF and Dac-RIF was 
observed yielding lower process efficiencies. Nevertheless, comparing to extraction by methanol or its 
mixture with acetonitrile the recovery of aqueous extraction is much improved (Table 4). 
Effect of hematocrit and blood spot volume
The biases caused at Hct ranges from 20 to 50% were within the acceptance limit of 15% for CLR 
and 14OH-CLR at all three QC level. For RIF and DAc-RIF, however, a clear upward trend in bias was 
observed as Hct increased, resulting in a bias range from -18.4 % to 28.0 %. Correcting with the respec-
tive hematocrit value, the upward bias trend was less steep, ranging from -8.9% to 15.8%. 
The bias range due to the variation in blood spot volume was from -7.8% to 8.9% for all four analytes at 
QC MED and HIGH. At LOW QC the blood spot volume of 30 µL resulted in negative biases as low as 
-23.6, -19.4, -17.6 and -20.6 % for RIF, DAc-RIF, CLR and 14OH-CLR, respectively. 
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Stability
A high stability was observed with CLR and 14OH-CLR in DBS in which no significant degradation 
occurred at 500C, 300C and at room temperature for 15 days, 30 days and 2 months, respectively. RIF 
and DAc-RIF showed stable at room temperature for up to two months. At higher temperature of 
300C and 500C, RIF and DAc-RIF were stable for 10 days and for 3 days, respectively. Longer storage at 
temperatures over 300C resulted in more than 15% degradation.
Clinical validation
Thirteen patients receiving rifampicin agreed to join the study. One patient experienced vomiting on 
the study day and was excluded. From the remaining twelve patients, eight pairs had RIF’s concentra-
tions under LLOQ (0.2mg/L for plasma and 0.15mg/L for DBS) both in plasma and in DBS. The correla-
tion coefficient between RIF’s concentration in DBS and plasma was 0.9067 and the slope of the regres-
sion line was 0.86 (n=28). The DAc-RIF concentrations lower than LLOQ (0.2mg/L for plasma and 
0.15mg/L for DBS) were observed in 16 pairs of samples. Two pairs of samples with DAc-RIF concentra-
tion above LLOQ for DBS (0.19mg/L and 0.23mg/L) yet below LLOQ for plasma were not included in 
regression. The correlation coefficient between DBS and plasma was 0.6856 (n=18) for DAc-RIF. Four 
MDR-TB patients treated with clarithromycin participated to the study and 12 pairs of DBS-plasma 
samples were taken. CLR and 14OH-CLR concentration were under LLOQ level in two pair of samples 
(0.1mg/L for plasma and 0.05 mg/L for DBS). Good correlations between DBS and plasma samples of 
CLR and 14OH-CLR were observed (r2=0.9752 for CLR and r2=0.9421for 14OH-CLR). The slope of the 
regression line of CLR was 0.7964 which was lower than 1 suggesting a higher concentration in plasma 
than in DBS. The metabolite of CLR showed an equal result between DBS and plasma (Figure 3).
DisCussion
This study showed that RIF, CLR and their active metabolites can be measured in DBS and show a good 
correlation with plasma. Therefore, method is suitable for therapeutic drug monitoring and pharma-
cokinetic studies. The analytical method is validated and the DBS specimen was proved to be very 
stable for a long period. In addition, a simple extraction procedure was developed to deal with the 
interaction of the analytes with the DBS matrix.
The challenge of developing a simple extraction method was to cope with low recoveries and/or sub-
stantial matrix effects for RIF and its metabolites observed after using acetonitrile or methanol or their 
mixtures as extraction solvents. As a consequence, the pre-validation experiment showed non-linear 
calibration curves and irreproducible results. The matrix effect was resulted from the blood matrix of 
DBS and whole blood. The presumed forming of the complex between RIF and endogenous compo-
nents in blood extract is a previous suggested theory (20,22). The formed complex was unstable and 
showed to have a slightly different retention time, while the complex showed in-source fragmentation 
back into the analyte during ionization. This caused a shoulder following the analyte peak and thus 
deteriorating the chromatographic quality of the analysis and lowering the peak height at the RIF’s 
retention time. The use of complexing agents such as EDTA and DFX to eliminate complex forming 
with endogenous substances during the extraction was unsuccessful for methanol and acetonitrile 
extracts. During method development it was observed that an aqueous extraction provided an appro-
priate environment for interaction between the DBS matrix and complexing agents. EDTA showed 
to improve the precipitation of the DBS extract yielding a cleaner supernatant. Without EDTA, the 
dirty extract produced a negative effect on the response of RIF and DAc-RIF but no such clear effect 
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was observed with CLR and 14OH-CLR. Interestingly, the precipitation appeared to be dependent on 
EDTA concentration. An EDTA concentration higher than 0.58 g/L showed sufficient for precipitation. 
The incorporation of EDTA recovered the response of the neat RIF’s solution containing Fe (III) but not 
of the DBS extract. It was supposed that RIF may interact with other endogenous components in DBS 
rather than Fe (III) only. It was reported that DFX as a ferric chelating agent improves the analytical 
response of artemisinin derivatives (25). In this study, adding DFX to the extraction solution recovers 
the response of RIF in the DBS extraction to approximately 100% (Table 3). 
The DBS sampling without a volumetric device like a pipette is confronted with an analytical bias 
resulting from variable Hct or blood volume of the spot. As Hct values increased higher concentrations 
were measured for the same concentration level for all four analytes. A significant bias occurred with 
Hct values extremely distant from the standardized value, Correction of the analytical result for its Hct 
value reduces this bias to an acceptable range (19). Biases of approximately 20% were observed with 
the blood spot of 30mL at LOW QC concentration. This may result from a chromatographic effect in 
which the analytes stay more in the centre part of the DBS. The use of a volumetric capillary may be 
considered to reduce this kind of bias (10,23).
The clinical validation in our study showed a good correlation between DBS and plasma concentra-
tions for CLR, RIF and 14OH-CLR. The results of DBS as a consequence can be used to predict the 
plasma concentration which is well investigated in pharmacokinetics study. The correlation coefficient 
for DAc-RIF was low (r2=0.69) that may result in error in predicting plasma concentration from DBS 
concentration. Because concentration of Dac-RIF is much lower than respective concentration of RIF, 
the TDM decision was affected at minor extent due to such error. It is noticeable that sample  under 
LLOQ levels of DBS and plasma samples was 100% matched for CLR, RIF and 14OH-CLR and 89% 
matched for DAc-RIF. This result at LLOQ level suggests that DBS sampling can also be useful to moni-
tor the adherence of patients.
One of the most attractive issues of DBS in bioanalysis is the stability. This study demonstrates that RIF 
and CLR and metabolites are stable up to 2 months under the room condition with the temperature 
of approximately 250C. All four substances also showed to be stable at 370C, which mimics a tropical 
climate and is common in the high burden areas like South Africa and Asia. In these conditions, CLR 
and its metabolite was not affected after 2 months whilst RIF and DAc-RIF were stable after 10 days of 
storage only. CLR and it metabolites also presented a high stability at high temperature up to 500C as 
no significant degradation was observed after 15 days. RIF and its metabolite were considered to be sta-
ble after 3 days of storage in that condition only. Although the stability of RIF and DAc-RIF was less than 
CLR, 10 days at 370C or 3 days at 500C could be enough for transporting sample even by normal post.
In conclusion, the rapid LC-MS/MS method was developed and thoroughly validated to simultane-
ously quantify RIF, CLR and their metabolites in dried blood spot. The role of EDTA and DFX as a 
chelating agent in the extraction was well investigated and suggests a potential application for other 
DBS analytical methods. The clinical validation showed a good correlation between the result of DBS 
and conventional sampling. The long term stability of the DBS specimen at high temperature could 
facilitate the TDM and pharmacokinetic studies of RIF and CLR even in resource limited areas.
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Table 3. Effect of different extracting solution on the matrix effect and recovery
Extracting solution
(ACN: MeOH)
14OH-CLR CLR DAc-RIF RIF
Matrix effect (%) 0:100 109 106 63 15
30:70 113 112 74 19
80:20 103 103 59 17
Recovery (%) 0:100 68 75 54 40
30:70 59 65 44 32
80:20 2 3 1 2
Data calculated from 3 replications 
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Table 6. Long term stability under different storage temperature (n=5)
Temperature Time 
(days)
CLR 14OH CLR RIF DacRIF
HIGH LOW HIGH LOW HIGH LOW HIGH LOW
250C 7 2.4 (3.8) 4.8 (7.7) 4.3 (3.3) 9.2 (9.7) -0.6 (3.4) 5.5 (4.3) 1.1 (5.9) 1.2 (12.7)
30 0.1 (3.8) 9.2 (3.8) 2.1 (5.0) 4.5 (5.2) -1.7 (2.6) -2.6 (5.2) -0.6 (5.7) 2.4 (3.2)
60 -5.5 (1.8) 7.8 (4.8) -3.0 (3.9) 3.0 (8.9) -14.5 (2.2) -4.3 (2.4) -11.5 (5.0) -3.3 (4.5)
370C 10 -7.0 (3.2) 10.7 (6.3) -0.6 (1.5) 1.4 (3.3) -14.1 (3.4) 0.6 (4.1) -11.1 (1.7) -4.8 (5.8)
20 -7.7 (4.8) 8.0 (6.1) -6.4 (4.5) -1.7 (4.5) -19.2 (1.7) -8.9 (5.8) -20.3 (2.5) -8.0 (7.1)
30 -6.7 (3.4) 13.9 (6.5) -4.4 (3.4) -0.2 (5.7) -28.2 (5.3) -15.0 (6.8) -26.4 (4.0) -15.7 (8.9)
500C 1 -0.8 (2.6) 8.2 (4.1) 3.6 (1.4) 1.5 (4.9) 0.8 (2.6) -1.2 (6.0) 3.2 (3.7) 5.8 (6.4)
3 3.9 (1.2) -0.7 (4.1) 8.8 (2.8) 5.7 (5.2) -9.1 (2.1) -9.8 (4.7) -5.5 (5.0) -11.9 (7.3)
7 0.0 (5.0) 2.0 (2.8) 6.0 (7.0) 5.0 (2.6) -19.0 (5.5) -15.7 (4.5) -14.0 (5.3) -18.4 (10.1)
15 -1.9 (3.8) 9.4 (4.4) -1.1 (3.0) -6.9 (6.4) -24.2 (5.4) -20.2 (5.0) -25.8 (7.0) -31.3 (12.2)
Result was presented as %Bias (%CV) of five replications
Figure 1. UV-VIS absorbance of the precipitated DBS extracts using different EDTA concentration.
a: ACN: water (v/v 3:1); b: Blank extraction using EDTA 1.54g/L in water; c: Extract of DBS using EDTA concentration of 0-0.38 mg/L 



















Simultaneous Determination of Rifampicin, Clarithromycin and Their Metabolites in Dried Blood Spot
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Figure 2. 
Representing chromatograph; A: LLOQ DBS sample; B: DBS sample of a TB patient at t=2h after administered rifampicin (DBS 
concentration RIF=11.00 mg/L, Dac-RIF=0.51 mg/L); C: B: DBS sample of a TB patient at t=2h after administered clarithromycin 























































Figure 3. Correlation between the DBS and plasma concentration
Uper-lelf: Rifampicin (n=28); Uper-right: Desacetyl Rifampicin (n=18) 
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absTraCT
linezolid is a promising antimicrobial agent for the treatment of multidrug-resistant tuber-
culosis (mDr-Tb), but its use is limited by toxicity. Therapeutic drug monitoring (TDm) may 
help to minimize toxicity whilst adequate drug exposure is maintained. Conventional plasma 
sampling and monitoring might be hindered by logistic problems in most parts of the world 
that may be solved by dried blood sampling (Dbs). The aim of this study is to develop and 
validate a novel method for TDm of linezolid in mDr-Tb patients using Dbs.
Plasma, venous Dbs and capillary Dbs specimens were obtained simultaneously from eight 
patients receiving linezolid. a Dbs method was developed and clinically validated by com-
paring Dbs with plasma results using Passing bablok regression and bland-altman analysis. 
This study showed that Dbs analysis was reproducible and robust. accuracy and between 
and within-day precision from three validation presented as bias and Cv were less than 17.2% 
for lower limit of quantification level (lloQ) and 7.8% for other levels. The method showed a 
high recovery of approximately 95% and a low matrix-effect of less than 8.7%. Dbs specimens 
were stable at 370C for 2 months and at 500C for one week. The concentration ratio of Dbs/
plasma was 1.2 (95%Ci: 1.12-1.27). linezolid exposure calculated from Dbs and plasma showed 
good agreement. 
in conclusion, Dbs analysis of linezolid is a promising tool to optimize linezolid treatment 
in mDr-Tb patients. an easy sampling procedure and high sample stability may facilitate 
TDm, even in underdeveloped countries with limited resources where conventional plasma 
sampling is not feasible.
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inTroDuCTion
Linezolid is used as a second line drug in the treatment of multidrug-resistant tuberculosis (MDR-
TB) due to its efficacy in vitro (21), in vivo (9) and in patients (1, 2, 14, 17, 34) against Mycobacterium 
tuberculosis. The World Health Organization (WHO) classifies linezolid as a reserve anti-tuberculosis 
drug for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB) 
(33). Linezolid is usually added to a treatment regimen consisting of anti-tuberculosis drugs for which 
the Mycobacterium tuberculosis is still susceptible. However, treatment with linezolid   may be limited 
by toxicity, such as time- and dose-dependent neuropathy or myelosuppression (17, 29), urging dose 
reduction or cessation of treatment with linezolid. Therapeutic drug monitoring (TDM) can be used to 
implement dose reductions to limit toxicity, whilst preventing inadequate exposure. Efficacy predict-
ing pharmacokinetic /pharmacodynamic (PK/PD) parameters, such as the area under the concentra-
tion-time curve to MIC ratio (AUC0-24h/MIC), might be helpful in evaluating linezolid dosages (1, 7, 26, 
32) . The AUC0-24h/MIC has been shown to be the best predictive model in a murine model (32), but evi-
dence from human data are lacking. Further PK/PD data from TB-programs or large studies are needed 
for the development of evidence based PK/PD parameters, such as an AUC0-24h/MIC ratio target. 
Linezolid treatment has been evaluated for TB treatment, in several case series (17, 23). However, nei-
ther drug susceptibility testing (DST) nor drug exposure assessment was performed for linezolid, mak-
ing it difficult to draw conclusions on efficacy (5). For instance, drug-interactions with other antimicro-
bial agents might have occurred and may have had an impact on linezolid exposure (6, 15). In addition, 
conventional drug exposure evaluation for TB drugs using plasma samples might have been hindered 
in these studies by logistical challenges (30). The use of dried blood spot (DBS) sampling may pro-
vide a helpful alternative to conventional plasma sampling through simplified sampling procedure and 
increased sample stability.  DBS sampling has been applied in the treatment of other infectious dis-
eases like malaria and HIV (30). Other advantages may include a lower required blood sample volume 
and lower biohazard risk of DBS samples compared to conventional plasma samples (12, 18, 30). Com-
pared to conventional sampling, DBS sampling may be hindered by inter and intra-patient hematocrit 
(Hct) variation causing different blood viscosity yielding a proportional analytical bias with Hct value. 
Furthermore, Hct may affect the drug blood / plasma partition ratio complicating the comparison 
with conventional plasma samples. In the development of a bioanalytical method for linezolid using 
DBS analysis important patient related factors like blood spot volume, Hct value (3, 24) and difference 
between capillary and venous blood, have to be assessed during validation. (12, 18, 25, 30). To enable 
individualized linezolid treatment the aim of this study was to develop and validate a method for DBS 
analysis and evaluate it in MDR-TB and XDR-TB patients. 
maTerials anD meThoDs
Patients
From September 2010 to March 2012, MDR-TB patients (≥18 years) were recruited from the Tubercu-
losis Centre Beatrixoord, University Medical Center Groningen (Haren, The Netherlands). Eligible for 
inclusion were patients receiving treatment with anti-tuberculosis drugs for which routine therapeutic 
drug monitoring was scheduled. Patients with bleeding disorders were excluded from the study. The 
study procedures were reviewed and approved by the local Ethics Committee. Patients receiving lin-
ezolid were included after providing written informed consent.
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Sampling was performed at least one week after the start of linezolid treatment to ensure the steady-
state was achieved. Venous blood samples were obtained our before drug intake and at 1, 2, 3, 4 and 
8 hours after dosing according to a previous study (2) and local procedures for TDM of TB drugs to 
be able to calculate drug exposure and other PK parameters. Venous dried blood spot (VDBS) speci-
mens were prepared by pipetting 50µL venous blood onto Whatman 31 ET CHR paper. The remaining 
venous blood was centrifuged at 3000 rpm for 5 minutes at room temperature to attain plasma which 
was stored at -200C until analysis. DBS specimens were obtained through a finger prick by dropping 
the blood directly on dried blood spot paper. DBS samples were obtained before drug intake, 2 and 
8 hours after dosing, representing low, high and medium linezolid blood levels respectively. Both the 
VDBS and DBS samples were left to dry at room temperature and stored in sealed plastic bags with 
desiccant sachets at -200C until analysis.
Dbs analysis
To quantify DBS samples an 8 mm-diameter disc was punched out of each blood spot. Extraction of 
these discs was performed by sonication with a frequency of 47 kHz during a period of 20 minutes 
using 500 µL of extracting solvent consisting of cyanoimipramine 0.3 mg/L (internal standard) and 
EDTA 1g/L in water. From this solution, a volume of 200 µL was added to 750 µL of acetonitrile. The 
samples were vortexed for 1 minute and subsequently centrifuged at 11000 rpm for 5 minutes. An 
injection volume of 5 µL was analyzed using a validated LC-MS/MS analysis method (16). The plasma 
samples were prepared and analyzed using the same method.
Dbs analytical method validation
The DBS analytical method was validated in accordance with the recommendation of US Food and 
Drug Administration’s (FDA) Guidance for Industry Bioanalytical Method validation (27). For the vali-
dation, blood was prepared by mixing plasma, red blood cell and linezolid stock solution to achieve 
blood at desire concentration and Hct. Subsequently, the validation DBS samples were prepared by 
pipetting 50µL of blood onto the paper. Linearity was assessed with 1/x2 weighting over a concentra-
tion range of 0.05-40 mg/L. Clinical relevant concentrations were well within the range of the assay 
standards (2). The within-day and between-day accuracy and precision were evaluated on four valida-
tion levels of LLOQ (lower limit of quantification), LOW, MED and HIGH at concentrations of 0.05, 
0.25, 15 and 30 mg/L, respectively. Each validation level was analyzed in fivefold on three consecutive 
days. The matrix effect and the recovery of linezolid from DBS were determined using a common 
method (18, 31). The stability of DBS specimens was assessed by storing validation DBS at ambient 
condition and 37oC after one week, two weeks and two months. As a worst case scenario the stability 
of DBS specimens was also assessed at 50oC after one day, two days and one week. The stability was 
evaluated at LOW and HIGH levels in fivefold by comparing the analytical result with the nominal 
concentrations. In addition to the criteria suggested in the FDA guideline (27), the impact on assay 
accuracy and precision due to the variations of Hct and blood spot volume were evaluated. For these 
purposes, Hct of 20, 25, 30, 35, 40, 45 and 50%, and blood spot volumes of 30, 50, 70 and 90 µL were 
assessed. During the method validation, blood spot volume and Hct were standardized at 50µL and 
35%, respectively. The set of Hct of 35% reflects the Hct in tuberculosis patients (3).
Pharmacokinetic and pharmacodynamic evaluation
Pharmacokinetic parameters were evaluated using a non-compartmental model of the KINFIT module 
of MW Pharm (version 3.9; Mediware, The Netherlands). The AUC0-12h was calculated using the trap-
ezoidal rule from 0 up to 12 hours and the AUC0-24h by doubling the AUC0-12h. The maximum concentra-
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tion (Cmax) was defined as the highest observed linezolid concentration with Tmax as corresponding 
time. The elimination half-life (t1/2) was calculated by dividing the natural logarithm of 2 (ln2) by the 
elimination constant (ke) as calculated by MW Pharm. The apparent clearance (Cl) of linezolid was 
calculated by dose/AUC0-12h. The volume of distribution (Vd) was calculated by dividing Cl with ke.
The drug susceptibility testing of the Mycobacterium tuberculosis isolates was performed at the Dutch 
National Mycobacteria Reference Laboratory (National Institute for Public Health and the Environ-
ment; RIVM) using the Middlebrook 7H10 agar dilution method (28). The AUC0-24h/MIC ratio, often 
used as a predictive pharmacodynamic parameter for efficacy, was calculated (32). 
statistics
In the method validation, the bias was defined as the difference (in percentage) between analytical 
result and the nominal concentration. The method was clinically validated by comparing the concen-
trations of DBS and VDBS with plasma concentrations using Passing Bablok regressions and Bland-
Altman analysis by applying the software tool Analyse-it 2.20Ò (Analyse-it Software, Ltd). Conversion 
factors, calculated from geometric mean (V)DBS/plasma concentration ratios, were used to calculate 
conversed DBS and VDBS concentrations(4). Subsequently, the conversed concentrations were used 
to calculate the AUC0-12h of DBS and VDBS. The agreement between AUC0-12h value of conversed DBS 
and plasma was evaluated using Bland Altman analysis. Spearman correlation and Wilcoxon signed-
rank test was applied to other comparisons. 
resulTs
Patients
Eight patients with a median age of 29 years (IQR: 24-33 years) were included in this study. The baseline 
characteristics are presented in Table 1. The median of Hct was 37.4% (IQR: 33.0-41.4%). At time of the 
study three of eight patients received linezolid 300 mg twice a day and five patients in a dose of 600 
mg twice daily. Isolates of seven patients showed resistance to first-line drugs isoniazide, rifampicin, 
ethambutol, pyrazinamide, and streptomycin. The isolate of one patient showed resistance to all first-
line drugs except pyrazinamide. All DSTs revealed resistance for rifabutin, whereas one isolate showed 
fluoroquinolone-resistance and three protionamide-resistances. None of the patients experienced 
significant discomfort from the finger pricks during DBS sampling which was supported by the fact 
that all completed the three consecutive samples in this study.
Dbs method validation
The DBS assay method showed linearity over the analytical concentration range. The pooled correla-
tion coefficient was r2=0.9947. The regression equation is: concentration= (0.1635±0.0025) ⩽ response 
+ (0.0001±0.0003). Within-day and between-day accuracy and precision showed CVs within accepted 
range. Within-day CVs ranged from 1.6% to 13.8% and between-day CVs from 3.5% to 10.2%. The mean 
measured concentration was within 98.7% to 106.3% of the nominal concentration. The bias caused by 
variable matrices, i.e. DBS and EDTA matrices, was less than 8.7%. The recovery of DBS extraction was 
between 94.1% and 97.2%. No significant linezolid degradation was observed after storing DBS at 500C 
for at least one week and at 370C or ambient temperature for two months as biases were less than 15%. 
Variation of blood spot volume between 30 µL to 90 µL had a minor impact on the assay accuracy as 
the bias ranged from -11.6% to 7.1%. The variation of Hct from 20% to 50% yielded biases within -7.6% to 
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6.8% and -12.5% to 5.7% for MED and HIGH level. Larger biases of -17.8% to 11.9% were observed at the 
LOW concentration level (0.25mg/L) (Table 2). 
Comparisons of Dbs, vDbs and plasma analysis
Significant proportional biases were observed in Passing Bablok regressions in which the slope of 
regression line between DBS and plasma was 1.28 (95%CI: 1.13-1.44) and VDBS and plasma was 1.46 
(95%CI: 1.40-1.54). The intercepts were –0.42 (95%CI: -1.72-0.17) and -0.67 (95%CI: -1.36-0.09), respec-
tively (Fig. 1).  In Bland–Altman analysis, the geometric mean concentration ratios of DBS and VDBS 
versus plasma were 1.20 (95%CI: 1.12-1.27) and 1.36 (95%CI: 1.32-1.40), respectively. The ratio of VDBS/
plasma was higher than that of DBS/Plasma (Wilcoxon signed-rank test, n=24, p<0.01). 95% limits of 
agreement were shown with less than 5% of the values falling out of the ranges (Fig. 2). 
Pharmacokinetic and pharmacodynamic evaluation
A median plasma AUC0-12h of 50.9 (IQR: 50.5-54.9) mg·h·L
-1 was observed following a dose of 300 mg 
and 126 (IQR: 121.6-127.6) mg·h·L-1 following a dose of 600 mg. Linezolid pharmacokinetic parameters 
are shown in Table 3. The concentration-time curves of plasma, DBS and VDBS are presented in Fig. 3. 
The AUC0-12h values of DBS and VDBS were calculated using the conversing factors 1.20 and 1.36 for DBS 
and VDBS respectively. The subsequent result showed a good agreement with plasma. All the values 
were within the 95% limit of agreement (Fig.4). The individual data for each patient for AUC0-12h attained 
from plasma and conversed (V)DBS concentrations and the respective AUC0-24h/MIC values are pre-
sented in Table 4. Patients that received a linezolid dose of 300 mg twice daily (n=3) had a median 
plasma AUC0-24h/MIC ratio of 236 mg·h·L
-1 (IQR: 219-322 mg·h·L-1) and patients that received 600 mg 
twice daily (n=5) had a median plasma AUC0-24h/MIC ratio of 508 mg·h·L
-1 (IQR: 486-1398 mg·h·L-1).  
DisCussion
This study showed that DBS analysis is an easy tool to individualize MDR-TB treatment with linezolid. 
In addition, this report presents a novel, validated method of analysis of linezolid in dried blood spots, 
with specimens that proved to be very stable over time. 
In previous studies on DBS analysis of other drugs, several technical factors were pointed out that have 
to be considered when interpreting DBS analysis, such as the effect of Hct and blood spot volume (12, 
13, 18, 30). For the analysis of linezolid in DBS, the effect of Hct seemed to be of minor concern. In this 
study, biases fell within accepted ranges for Hcts between 20-50%. These Hcts cover an even broader 
range than clinical Hcts found in TB patients in literature, i.e. 35.4±6.7% (3), and in this study 37.4±4.4%. 
Based on these findings, the standardization of Hct at 35% during DBS validation is acceptable. Fur-
thermore, variation of blood spot volume between 30-90µL had little effect as biases were within 15%.
Despite the minor influence of technical factors, i.e. Hct value and blood spot volume, physiological 
factors are also mentioned in literature to possibly limit the applicability and interpretation of DBS 
analysis (13). Such a factor might be differences between plasma concentration and whole blood con-
centration. This study shows that concentration of linezolid is higher in blood than in plasma. This 
is caused by different binding capacity to plasma proteins and blood cells. Furthermore, concentra-
tions of linezolid were higher in VDBS than in DBS. This might be caused by differences between the 
capillary and venous blood (13, 25, 30). Nevertheless, the concentration of DBS and VDBS specimens, 
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both showed good correlation with plasma concentration. To compensate for these differences, we 
propose conversion factors of 0.83 (1 / 1.20) for DBS and 0.74 (1 / 1.36) for VDBS to calculate corre-
sponding plasma values. After the conversion, good agreement between AUC0-12h of DBS and plasma 
was observed. 
A meta-analysis showed that a ≤600 mg linezolid daily dose resulted in lower frequency of either 
adverse event or adverse events necessitating treatment discontinuation than the dose of >600 mg 
daily (8). Among the published data, the lowest rate of adverse effects was observed with a dose of 
300 mg once daily (17). Nevertheless, lowering the dose clearly results in lower exposure to the drug 
(2, 19). In addition, interpatient variability and possible drug-drug interactions may lead to under- or 
over-exposure. Therefore, treatment with a fixed dose may be questionable (6, 11, 22, 26). The applica-
tion of TDM for linezolid can help avoid under- or overexposure which may occur in 30 to 40% of the 
cases (20). 
In this study, all patients had Mycobacterium tuberculosis isolates with a MIC ≤0.5mg·L-1 for linezolid. 
With a dose of 600 mg (n=5) twice daily, very high AUC0-24h/MIC ratios  were reached(10), so dose 
reductions could be implemented to prevent time- and dose-dependent toxicity. Furthermore, a high 
correlation of AUC0-24h/MIC values between conversed DBS and plasma (Spearman’s rho=0.976, n=8) 
was observed. This suggests that TDM using DBS may result in identical interventions compared with 
conventional plasma sampling. Therefore, adaptive dosing of linezolid to prevent potential toxicity and 
to assure therapeutic exposure is feasible using DBS.
The high stability of DBS specimens can minimize the logistic burden of conventional sampling in lim-
ited-resource areas. With a simple instruction, the DBS samples can be performed easily and sent to 
equipped facilities for analysis by mail (12, 30). This could enable the TDM in TB-programs worldwide 
including resource limited settings where MDR/XDR-TB epidemic is a growing problem. TDM using 
DBS for MDR/XDR-TB should be especially considered in areas where HIV or malaria co-infections are 
highly prevalent as DBS has been successfully applied to monitor the treatment of such diseases (30).
Since treatment of MDR/XDR-TB is long and complicated by adverse drug reactions, TDM of linezolid 
with DBS could be used to optimize drug exposure during treatment. In conclusion, this study pre-
sents a novel, validated analysis of linezolid in DBS specimens that is suitable for optimization of lin-
ezolid treatment of MDR-TB. Advantages include a very simple, low biohazard risk sampling method 
using a finger prick, easy logistics and very good stability of DBS specimens. 
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FIG 1 
Passing-Bablok regression between measurements in DBS/VDBS samples and plasma: VDBS-plasma regression line (dashed line, 
cross), slope of 1.46 (95% CI, 1.40 to 1.54) and intercept of -0.67 (95% CI, -1.36 to -0.09); DBS-plasma regression line (solid line, 
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FIG 2 
Bland-Altman plot of linezolid concentration ratios in DBS and VDBS samples versus plasma: solid line, mean ratio; dashed line, 
limit of agreement (mean ratio ± 1.96 × standard deviation of the ratio).
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FIG 3 
Concentration-time curves of linezolid in plasma (closed circle, solid line), VDBS samples (open circle, dashed line), and DBS 
samples (opened square, dotted line). Plasma and VDBS data are presented as means and standard deviations. For visual purposes, 
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FIG 4 
Bland-Altman plot of AUC0–12 for linezolid from corrected DBS versus AUC0–12 plasma samples. Solid line, mean difference; dashed 










































Table 1. Baseline demographics of study patients (n=8)
Parameter Value 




Bodyweight (kg) 60.5 [55.8 - 61.5] a
Height (m) 1.69 [1.67 – 1.76] a
Body mass index (kg/m2) 20.1 [19.0 - 21.4] a






Hemoglobin (mmol/liter) 7.0 [6.4 - 8.8] a, b
Hematocrit (%) 37.4 [33.0 - 41.4] a, c
TB treatment other than linezolid (no. of patient)
 Moxifloxacin 7 
 Amikacin/Kanamycin 6 
 Ethambuthol 5 
 Cotrimoxazole 3 
 Clofazimine 2 
 Ertapenem 2 
 Pyrazinamide 1 
a Median value (IQR); b Reference values for healthy subjects, 7.5 to 9.9 mmol/liter (female) and 8.7 to 10.6 mmol/liter (male); 
c Reference values for healthy subjects, 37.0 to 47.0% (female) and 42.0 to 52.0% (male); d n/N, number of TB patients with other 
infections/total number of TB patients.
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Table 2. Summarized results of the validation of DBS analysis 
Validation levels (n=5)e
Validation criteria LLOQ LOW MED HIGH
Nominal concentrations (mg·L-1) 0.05 0.25 15 30
Reproducibility a
 Accuracy (% Bias) 4.5 6.3 3.2 -1.3
 Within-day precision (% CV) 13.8 4.0 4.1 1.6
 Between-day precision (% CV) 10.2 3.5 6.1 7.7
 Overall precision (% CV) 17.2 5.3 7.4 7.8
Matrix effect (%) 2.9 8.7 1.9
Recovery (%) 95.5 94.1 97.2
Effect of blood volume (range of % Bias) b -2.9 - 4.1 -11.4 - 7.1 -11.6 - 9
Effect of hematocrit (range of % Bias) c -17.8 - 11.9 -7.6 - 6.8 -12.5 - 5.7
Stability d
 1 week at 500C (% Bias) 6.7 -3.4
 2 months at 370C (%Bias) -10 -5.9
 2 months at ambient temperature (% Bias) -2.5 -2.0
a: data from 3 separated validation days; b: comparison with sample of standardized blood spot volume (35µL); c: comparison with 
samples of standardized hematocrit (35%); d: present data from the last time of the period only; e: number of replicates
Table 3. Steady state pharmacokinetic parameters of linezolid in plasma a  
Parameter 300mg (n=3) 600mg (n=5)
AUC0-12h (mg · h/liter) 50.9 [50.5 – 54.9] 126.9 [121.6 – 127.6]
Cmax (mg/liter) 8.8 [7.8 – 8.9] 16.5 [14.4 – 16.5]
Tmax (h) 1.9 [1.9 – 4.8] 1.9 [1.7 – 3.0]
T1/2 (h) 4.6 [4.0 – 6.9] 7.5 [7.3 – 7.9]
Cl (liters/h) 4.9 [3.8 – 5.1] 3.1 [3.0 – 3.1]
Vd (liters) 32.6 [29.4 – 34.4] 34.8 [32.9 – 41.6]
a Data are presented as medians (IQR); All patients (n = 8) received linezolid twice daily.
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Table 4. Pharmacokinetic and pharmacodynamic parameters of linezolid using concentrations in plasma, VDBS, and DBS
Patient Dose (mg)a MIC  
(mg/liter)
AUC0-12h (mg · h/liter) AUC0-24h/MIC
Plasma VDBS b DBS b Plasma VDBSb DBSb
1 300 0.5 50.1 46.7 51.5 201 187 206
2 300 0.25 50.9 54.2 50.7 407 433 405
3 600 0.5 121.6 118.1 112.1 486 472 449
4 600 <0.125 127.6 130.9 114.2 >2042 >2094 >1827
5 600 0.5 126.9 132.0 140.2 508 528 561
6 600 0.5 66.6 69.4 64.2 266 278 257
7 300 0.5 58.9 46.1 42.4 236 184 170
8 600 0.25 174.7 183.1 189.6 1398 1465 1517
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Our research emphasizes new approaches to tuberculosis (TB) control in developing countries where 
serious and complex TB epidemics may threaten the Millennium Development Goal for TB (2015: halv-
ing deaths due to TB compared with baseline of 1990; 2050: eliminating TB as a public health issue) 
(1). In developing countries, National Tuberculosis control Programs (NTPs) known as public sector 
play the main role in the TB control mission. Other facilities, including private healthcare, also provide 
services but seem to be poorly connected with NTP (2,3). Studies show that private healthcare is a 
potential source of delayed diagnosis of TB, therefore increasing the risk of TB transmission within the 
community (4,5). 
Current therapeutic strategy against TB, updated for the latest scientific developments, has saved 
many lives. The application of Directly Observed Therapy, Short Course (DOTS) in TB chemotherapy 
is highly effective, ensuring adherence of the patient to a standardized regime and significantly increas-
ing the cure rate up to 90% (1,6). Nevertheless, the possibly of failed treatment, relapse or development 
of drug-resistant TB still exists. In addition, the community is being challenged by multidrug-resistant 
(MDR)/extensively drug-resistant (XDR) tuberculosis and HIV-TB comorbidity. Unfortunately, the 
numbers of available drugs for MDR/XDR-TB are limited (6). In combination with HIV comorbidity, the 
high potential of drug-drug interactions further limits the selection for chemotherapy (7,8). The anti-
TB drugs left are less effective and more toxic. Currently, about nine compounds are in the pipeline 
of clinical development and it will take time before they are routinely applied in TB treatment (9,10). 
While waiting for new effective drugs, optimizing the use of currently available ones is a judicious 
approach. According to the treatment guideline of WHO, the currently available TB drugs are classi-
fied into five groups as presented in the following Table (6).
Table. Antituberculosis drug classification of WHO
Group 1: First-line oral antituberculosis drugs
 Isoniazid, rifampicin(#), ethambutol, pyrazinamide, rifabutin
Group 2: Injectable antituberculosis drugs
 Kanamycin, amikacin, capreomycin, streptomycin
Group 3: Fluoroquinolones
 Levofloxacin, moxifloxacin(#), ofloxacin
Group 4: Oral bacteriostatic second-line antituberculosis drugs
 Ethionamide, protionamide, cycloserine, terizidone, p-aminosalicylic acid
Group 5: Antituberculosis drugs with unclear anti-TB efficacy
 Clofazimine, linezolid(#), amoxicillin/clavulanate, thioacetazone, clarithromycin(#), imipenem, 
(#): Dried blood spot analysis methods are developed
The answer from private pharmacies to Tb control
In Vietnam, a high tuberculosis burden developing country, previous studies have identified pri-
vate pharmacies as the highest potential source causing delay in TB diagnosis and treatment (11,12). 
Although private pharmacies are not in charge of making confirmed diagnoses of TB cases, they are 
the healthcare provider that TB patients normally visit to ask for healthcare advice (13-15). The ability 
to identify a case suspected of TB is therefore important for further advice. If the private pharmacy 
cannot notice the suspected symptoms of TB, selling non-TB drugs or referring the patient to non-TB 
healthcare are common-sense decisions (16). Even when patients suspected of TB can be detected, 
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the decision to refer for diagnosis is still an uncertain one (17). We observed that the ability to detect 
TB-suspected cases and the willingness of private pharmacies to refer the case to TB healthcare was 
related to awareness of healthcare providers (HCPs) about the NTP’s free treatment policy. A lower-
than-expected awareness about free treatment in NTP among HCPs may reflect two issues: (1) the 
collaboration between NTP and private pharmacies is still insufficient, and (2) the current massive 
education program for community pharmacists neglects the TB control mission.
The involvement of private pharmacies in dispensing anti-TB drugs is also of great concern. Previous 
studies show that private pharmacies dispense anti-TB drugs, including self-prescription for TB patients 
(18) . Because private pharmacies are not commonly updated on the most recent information from the 
WHO, the treatment outcome is generally poor (19,20). In this study we also found that anti-TB drugs 
were partly available or unavailable in private pharmacies. Only some anti-TB drugs were intended to 
be dispensed for TB treatment purpose, and only by prescription. This was confirmed by the simulated 
patient method, as no self-prescription of anti-TB drugs was generated. This result suggests that NTP 
and the authority were successful in controlling dispensing of anti-TB drugs in private pharmacies (16). 
Our study nonetheless addressed potentially improper dispensing of rifampicin as the core first-line 
drug for susceptible TB, and fluoroquinolones as crucial group for MDR-TB treatment (21). These drugs 
are commonly available in private pharmacies and are dispensed for the treatment of conditions other 
than TB, also without prescription. Forty nine (36%) interviewees in private pharmacies claimed that 
they were willing to dispense fluoroquinolones to suspected TB patient. Using the simulated patient 
method, eight private pharmacies were willing to dispense fluoroquinolones to a patient suspected 
of TB. The risk of emerging MDR/XDR TB from a high epidemic area being exposed to such mono-
therapies is undeniably possible (22). Further research is warranted to estimate the risk of improper 
dispensing practices presented in our study. 
Dried blood spot as a new tool for Tb treatment individualization
Optimal dosage of current anti-TB drugs is still an issue of controversy (23-26). Individual variability in 
pharmacokinetics is common for anti-TB drugs (27,28). Pharmacokinetic variation is the consequence 
of a complex combination of factors such as race, genetics, weight, comorbidity, diabetes and HIV. 
Recent studies show that pharmacokinetic variability is significantly associated with failure of therapy 
and ADR in patients (29,30). This suggests that individualized dosing for tuberculosis may be more 
effective than standardized dosing. Furthermore, adverse effects and toxicity commonly occur during 
the treatment, especially with second-line drugs (31,32). Drug overexposure causing toxicity is difficult 
to predict if the blood concentration is not measured. Individualized dosing using therapeutic drug 
monitoring (TDM) can be applied to optimize the treatment (27). Indeed, TDM can help patients with 
persistent or resistant TB, HIV-TB and diabetes-TB (33). To date, TDM has become practice in the treat-
ment of TB in a limited number of centers with developed logistics and facilities (34-41). However, 
TDM targets TB patients including MDR/XDR-TB, and HIV-TB can be found more in low- or middle-
income countries with limited resources. In these areas, TDM using conventional liquid sampling like 
serum and plasma faces many logistic obstacles (42). For conventional TDM these may include lack of 
trained healthcare staff for venous sampling and a cooled chain for sample storage and transportation 
(42). Recent advances in bioanalytical technology, particularly LC-MS/MS, makes DBS an impressive 
tool to overcome such obstacles (42,43). We developed methods of analysis using dried blood spot 
sampling for rifampicin, moxifloxacin, clarithromycin and linezolid, and proved the validity of those 
methods to determine drug exposure in TB patients. In the classification of the WHO guideline for TB 
treatment, rifampicin is the core first-line drug for the treatment of susceptible TB, while moxifloxacin 
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shows to be the most potential fluoroquinolone for the treatment of MDR/XDR-TB. The individual 
pharmacokinetic variability of rifampicin and moxifloxacin is high and TDM is suggested (28,44-47). 
Linezolid and clarithromycin are classified as group-5 anti-TB drugs for the treatment of MDR/XDR-TB. 
Linezolid proved its efficacy on MDR/XDR-TB but its high toxicity suggests individualized treatment 
may be beneficial (31). 
The attractive characteristic of DBS sampling is that the specimens are stable at ambient or high tem-
perature. Our research showed that moxifloxacin, rifampicin, clarithromycin and linezolid are stable at 
room temperature for up to one or two months. Consequently, equipment to ensure a low tempera-
ture for sample storage and transportation is not necessary. At a temperature of 37°C this mimics the 
conditions in tropical countries or those of 50°C that may occur during transportation; rifampicin, lin-
ezolid and clarithromycin showed acceptable stability. These impressive data support that TDM using 
DBS sampling requires minimal logistics and that individualized dosing for TB outpatients in low- and 
middle-income areas is feasible (48-50).
We reviewed recent papers to gather experience of previous studies to facilitate the development of 
our methods (42). Our results provided deeper understanding about previous opinions on analytical 
and sampling technique of dried blood spots. We emphasized that hematocrit and blood spot volume 
impacted on analytical results to some extent. In general, analytical concentrations of all investigated 
drugs showed upward trend biases as blood spot volume increases. However, this effect was trivial and 
could be omitted. Therefore, DBS specimens can be collected regardless of precise volumetric devices 
like pipettes, and this is much convenient for sampling in resource-limited areas. Extreme hematocrit 
values may introduce significant biases (more than 15%) to the analytical results of drugs. The viscosity 
of the blood appears to be the main influencing factor because correcting for spot size can neutralize 
such bias (16,42,49,50). Hematocrit values of patients necessary for calculating the correction are nor-
mally available in medical records. It is noticeable that the extreme values of hematocrit at 20% or 50% 
presented in analytical method development are not common among TB patients. The DBS analytical 
results can therefore be interpreted without correction, as bias remains below 15%. With extremely 
low or high hematocrit, clinical pharmacists may consider correction if they find it necessary. 
During development of analytical methods using LC-MS/MS matrix effect and carry-over may be 
hurdles to overcome. We presented a logical approach to troubleshoot the carry-over when analyz-
ing rifampicin in plasma (51). Without carry-over this method is a good starting point for developing 
a DBS analytical method. Endogenous components from the DBS had a significant influence on the 
results. As high sample throughput should be realized for methods of analysis to be performed in daily 
practice, solid phase or liquid-liquid extraction should be avoided. Interaction between rifampicin and 
endogenous components in DBS was explored, and it appeared that adding complexing agents could 
suppress this effect. The validated method with simple extraction and precipitation is very quick, pro-
viding a high sample throughput (49).
The clinical validation in TB patients made the developed analytical methods applicable to clinical 
pharmacokinetics studies and to individualized patient care. To be able to compare DBS analytical 
results with the available pharmacokinetic data, which is mainly obtained based on plasma/serum 
sampling, clinical validation in TB patients had to be performed. Biases between the concentrations in 
DBS and plasma, which may have resulted from numerous physiological factors, are common (42). In 
our research, biases observed were negative or positive depending on the drugs (48-50). These biases 
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can be minimized by correcting with conversing factors attained in clinical validation. Corrected DBS 
concentrations after conversion can predict the plasma level. Our study demonstrates that using dried 
blood spot, PK/PD parameters can be accurately estimated. A high correlation of linezolid AUC0-24h/
MIC values between conversed DBS and plasma (Spearman’s rho=0.976, n=8) was observed. With 
the standard dose of 600 mg (n=5) twice daily, very high AUC0-24h/MIC ratios were reached (52). Dose 
reductions should therefore be implemented to prevent time- and dose-dependent toxicity. This sug-
gests that TDM using DBS may result in identical interventions compared with conventional plasma 
sampling. Adaptive dosing of linezolid to prevent potential toxicity and to assure therapeutic exposure 
is feasible using DBS (48). Because therapeutic exposure can be determined by using DBS sampling 
and analysis, patients with malabsorption or poor adherence can be detected (49). The drug resistance 
that emerges from monotherapy of concomitant TB drugs can be minimized. 
A previous study presented that DBS sampling is easy to perform and with minimal invasion to 
patients (53). Although no such evaluation was carried out during clinical validation of our study, we 
did not encounter difficulties with DBS sampling and all samples were collected as planned. In addi-
tion, analytical methods were developed with a run time of three to four minutes per sample, ensuring 
the laboratory could handle a large number of measurements (48-50). Easy sampling, simple sample 
preparation and throughput analytical method can further facilitate the application of DBS in an actual 
clinical setting.
future perspectives
Our work contributes to new scientific and programmatic views for TB control strategies, especially 
in developing countries like Vietnam. The results of our research strengthen our belief that program-
matic intervention on the knowledge of HCPs in private pharmacies can improve TB referrals and 
shorten delays. The involvement of private pharmacies in the public-private mix program can reduce 
delays, save healthcare costs and increase case detection. As education is one component of Good 
Pharmacy Practice (GPP) for pharmacists in private pharmacies, our finding suggests that the authority 
who certifies GPP may consider incorporating knowledge of TB control into this aspect. 
By using DBS sampling the logistic obstacles of conventional TDM could be omitted. We propose 
a programmatic paradigm of TDM for TB treatment in which the DOTS practice, connected with a 
central, well-equipped laboratory and clinic, play an important role (Figure). 
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Figure. 
Programmatic paradigm for implementation of TDM on TB patients using dried blood spot sampling; solid arrows: sample 
transport; dashed arrows: information communication.
TDM requires multidisciplinary collaboration therefore application should preferably be limited to a 
targeted group of patients only. In combination with limited sampling strategies, DBS can be used for 
further individualization of TB treatment (54). Clinical pharmacists should be involved in this proce-
dure to give advice to physicians regarding optimal dosage. Skeptics may raise questions about the 
high cost of TDM services yet they should consider the extreme cost for treatment of MDR/XDR-TB 
that may be prevented by TDM (55). A study on costs and benefits of DBS may provide the answer to 
this question.
With the advance of DBS sampling, longitudinal data of pharmacokinetic measurements can be fea-
sible. Longitudinal data with repeated measurement during treatment is necessary to evaluate the 
within-patient variability in pharmacokinetics parameters which is still not well-investigated (27). 
Within the limits of this thesis we developed analytical methods for four representative anti-TB drugs, 
and proved the feasibility of DBS sampling for treatment individualization. Further analytical methods 
for other TB drugs are required to convey this tool to the clinical setting. With the highly effective 
drugs in group 1, group 2 and group 3 of the WHO classification, treatment individualization to ensure 
sufficient exposure can be performed in special subgroups of patients who are at risk of failure or run 
the risk of progressing to MDR/XDR-TB. With the drugs in group 4 or group 5, which contribute to 
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Developing DBS analytical methods for agents in the pipeline of clinical development may accelerate 
the application of this tool in the future. Cautious use of such new agents is required to preserve their 
pharmacological efficacy.
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The Millennium Development Goal for tuberculosis (TB) of halving deaths due to TB in 2015 compared 
with the baseline of 1990 and eliminating TB as a public health problem by 2050 is challenged by prob-
lems such as the emerged drug resistance and the synergy with HIV infection. This thesis emphasized 
the clinical pharmacology aspects related to TB control in the developing world, where TB epidemics 
are serious and complex.
In Part 1 of this thesis we performed a field study using simulated patient methods and interviews 
in sequence, to explore the TB control activities of healthcare workers (HCPs) in private pharmacies 
in Hanoi, Vietnam. In Chapter 2 we addressed the fact that nearly half of HCPs in private pharma-
cies do not refer suspected tuberculosis patients, possibly contributing to the delay in diagnosis and 
treatment. This delay can contribute to worsening the epidemic in such urban areas because patients 
with active TB can increase the transmission of this disease to the community. Only 11 (9%) HCPs 
referred a simulated tuberculosis patient to a tuberculosis care facility and were considered to cause 
no delay. In addition, we detected factors that predict tuberculosis case detection skills and referral 
decisions in private pharmacies. Using penalized logistic regression, we explored that the awareness 
of free treatment in the National Tuberculosis Program (NTP) predicted a higher rate of direct referral 
to TB facilities and a better ability to detect TB from a paper, fictitious case. Those Pharmacies certified 
with Good Pharmacy Practice (GPP) were less likely to refer simulated patients to TB facilities than 
non-GPP pharmacies.
Chapter 3 described the availability of first-line and second-line anti-TB drugs in private pharmacies. 
In general, anti-TB drugs were not frequently presented in private pharmacies. However, private phar-
macies nearby the two TB hospitals of Hanoi were more likely to store anti-TB drugs. This subgroup 
may contribute more to TB control activity in a public-private mix strategy than referral of TB suspects 
only. Improper dispensing of rifampicin and fluoroquinolones was also addressed. Approximately 31% 
of the pharmacies dispensed rifampicin for covering an open wound, while about 36% of pharma-
cies were willing to sell fluoroquinolones to suspected patients. Actually, simulated patients obtained 
fluoroquinolones from eight private pharmacies for highly suspected TB symptoms. Because fluoro-
quinolones are back-bone drugs for multidrug-resistant TB (MDR-TB), the dispensing of these drugs 
should deserve more attention. 
In Part 2 we emphasized dried blood spot (DBS) sampling and analysis of anti-TB drugs, which can 
applied to treatment optimization. The patient variation in pharmacokinetics of anti-TB drugs is 
reported to be common. The consequence is that many patients treated with a standardized regimen 
can have subtherapeutic drugs levels, while others may suffer toxicity because of overexposure. Recent 
clinical model and meta-analysis reveal that pharmacokinetic variability is responsible for treatment fail-
ure and the emerged drug-resistance. The development of a tool for easily implementing therapeutic 
drug monitoring in the developing world, where TB epidemic is an increasing problem, is required. 
In chapter 4 a review on recent DBS analysis methods was performed to identify the pros and cons 
of DBS sampling and analytical methods. The opportunity to apply DBS to TB control in an actual 
resource-limited setting was also discussed. Technical and clinical aspects of DBS analytical method 
development were summarized in order to support the future appropriate establishment and applica-




In chapter 5, a simple and fast analytical method was developed to determine moxifloxacin in DBS 
specimens using LC-MS/MS. Moxifloxacin is potential fluoroquinolones against MDR-TB, and has 
been evaluated in a phase-3 study. The developed method has shown to be linear, selective, accurate 
and precise. Critical factors including hematocrit, blood spot volume that may impact the accuracy 
and precision of the method were also evaluated. Blood spot volume appeared to have a minor impact 
on the accuracy and the precision of the method; therefore use of a volumetric device is not necessary. 
Hematocrit showed a proportional correlation with the analytical bias, and for patients with extreme 
hematocrit value correction could be considered. The impact of hematocrit on the analytical bias 
partly originated from the spreading of blood on paper due to its viscosity. In the clinical validation, 
DBS concentration showed a high linear correlation with plasma concentration (r2=0.966). The slope 
is 1.49 (95% confident interval 1.32-1.77), suggesting that moxifloxacin concentrated more in blood cells 
than in plasma. Moxifloxacin showed a high stability in DBS specimens in which no significant degrada-
tion occurred at ambient temperature after at least one month.
In Chapter 6a and Chapter 6b a throughput method was developed for simultaneous determina-
tion of rifampicin, clarithromycin and their active metabolites, 25-desacetyl rifampicin and 14 hydroxy 
clarithromycin in DBS specimens. Rifampicin is a back-bone first-line anti-TB drug with a high sterilizing 
activity in vivo. The high variability in patient pharmacokinetics and the controversy about the optimal 
dose of this drug suggest that TDM is beneficial. First, we describe a stepwise approach to trouble-
shoot the carry-over observed in previously developed methods. By replacing the polar end-capped 
C18 phase column, the carry-over was eliminated (Chapter 6a). Second, we applied this finding to 
develop an analytical method for DBS specimens. By incorporating ethylenediaminetetraacetic acid 
(EDTA) and deferoxamin in the extraction, the interaction between rifampicin and the endogenous 
component of DBS causing a bad “matrix effect” was precluded and the overall process efficiency 
was improved. The clinical validation showed a good correlation between DBS and plasma concen-
trations of rifampicin, clarithromycin and 14 hydroxy clarithromycin, suggesting that DBS analytical 
results can be used to predict plasma exposure. Also, the concentrations detected under lower limit 
of quantification were identical when using DBS and plasma specimens. DBS samples can therefore be 
collected to detect nonadherence of patients. To enable reliable results when applying DBS sampling 
in resource-limited settings, a comprehensive stability test was implemented. In contrast with low sta-
bility in liquid samples, rifampicin showed to be highly stable in DBS specimens (ambient temperature 
for 2 months, 37°C for 10 days and 50°C for 3 days). The sample could then be stored and transported 
without the need for equipment to ensure low temperature conditions (Chapter 6b). 
In Chapter 7, the opportunity for applying DBS sampling and analysis to the TDM was described 
more in detail with linezolid. A developed and validated DBS analytical method proved reproducible 
and robust. Clinical validation was implemented by comparing DBS with plasma results using Passing-
Bablok regression and Bland-Altman analysis. The ratio of the concentration of linezolid in DBS sam-
ples to that in plasma was 1.2 (95% confidence interval 1.12 to 1.27). Linezolid exposure calculated from 
concentrated DBS samples and plasma showed good agreement. A high correlation of AUC0-24/MIC 
values between DBS and plasma (Spearman’s rho = 0.976, n = 8) was observed. This suggests that 
TDM using DBS may result in interventions identical to those with conventional plasma sampling. 
Furthermore, linezolid showed a high stability in DBS specimens at 37°C for 2 months and even at the 
high temperature of 50°C for one week. Hence adaptive dosing of linezolid to prevent potential toxic-
ity and to ensure therapeutic exposure is feasible using DBS sampling even in limited-resources areas.
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In Chapter 8 we discussed the impact of our results on TB control in the developing world. The posi-
tion of private pharmacies in the TB control strategy of the National Tuberculosis Program of Vietnam 
was addressed and revised. The requirement of individualization of TB chemotherapy in the devel-
oping world using DBS sampling was discussed. We proposed a programmatic paradigm for TDM 
implementation supporting clinical decisions in the treatment of TB in limited-resource areas using 
DBS sampling and analysis.
Tóm TẮT 
Mục tiêu thiên niên kỷ của tổ chức y tế thế giới đối với bệnh lao là tới năm 2015 sẽ giảm một nửa số ca 
tử vong do lao so với năm 1990 và tới năm 2050 sẽ loại bỏ bệnh lao khỏi danh sách các bệnh cộng đồng. 
Tuy nhiên, mục tiêu này hiện đang bị thách thức do sự phát triển của tình trạng lao kháng thuốc và đồng 
nhiễm lao với HIV. Luận án này tập trung vào một số vấn đề dược lý lâm sàng liên quan đến việc kiểm 
soát bệnh lao ở các nước đang phát triển, nơi thường có tình hình dịch tễ lao nghiêm trọng và phức tạp.
Trong phần 1, chúng tôi thực hiện một nghiên cứu thực địa có sử dụng phương pháp đóng vai bệnh 
nhân đi kèm với phương pháp phỏng vấn nhàm tìm hiểu về hoạt động của các nhân viên y tế tại nhà 
thuốc tư nhân trong công tác phòng chống lao tại Hà Nội. Trong chương 2, chúng tôi chỉ ra rằng có 
tới gần một nửa nhân viên y tế tại nhà thuốc tư nhân không giới thiệu bệnh nhân nghi ngờ lao đi khám 
làm chậm trễ việc chẩn đoán xác định khởi đầu điều trị. Việc chậm trễ này có thể làm xấu thêm tình 
hình dịch tễ tại một khu vực nội thành đông dân cư như Hà Nội bởi vì bệnh nhân trong giai đoạn lao 
tiến triển có thể gây tăng lây nhiễm ra cộng đồng. Chỉ có 11 (9%) nhân viên y tế giới thiệu người đóng 
vai bệnh nhân đến các cơ sở khám và điều trị lao và do đó có thể coi là không gây chậm trễ trong việc 
chẩn đoán. Hơn nữa, chúng tôi cũng chỉ ra các yếu tố có liên quan đến kĩ năng phát hiện bệnh nhân lao 
và quyết định giới thiệu đi khám của nhân viên tại nhà thuốc. Bằng phân tích hồi quy penalized logistic, 
chúng tôi thấy rằng việc các nhân viên y tế ý thức về chính sách khám và điều trị miễn phí tại Chương 
trình chống lao quốc gia sẽ có khả năng phát hiện ca lao từ ca giả định tốt hơn cũng như sẽ giới thiệu 
bệnh nhân nghi ngờ lao đi khám lao nhiều hơn. Các nhà thuốc có chứng chỉ thực hành nhà thuốc tốt 
dường như ít giới thiệu trực tiếp đến các cơ sở khám lao hơn. 
Trong chương 3, chúng tôi mô tả về tính sẵn có và việc cung cấp thuốc chống lao tuyến một và tuyến 
hai tại nhà thuốc tư nhân. Nhìn chung, các thuốc chống lao không xuất hiện nhiều ở các nhà thuốc tư 
nhân. Tuy nhiên, các nhà thuốc tư nhân gần hai bệnh viện lao tại Hà Nội có vẻ như lưu trữ thuốc điều trị 
lao nhiều hơn. Do đó, nhóm nhà thuốc này có thể tham gia nhiều hơn vào các hoạt động trong chiến 
lược phối hợp công tư về phòng chống lao chứ không chỉ thực hiện việc giới thiệu bệnh nhân nghi ngờ 
lao. Việc bán rifampicin và các flouroquinolone một cách không hợp lý cũng được chỉ ra trong nghiên 
cứu này. Có khoảng 31% số nhà thuốc bán rifampicin để rắc vào vết thương trong khi 36% nhà thuốc sẵn 
sàng bán các thuốc thuộc nhóm fluoroquinolone cho bệnh nhân nghi ngờ lao giả định. Trên thực tế, 
người đóng vai bệnh nhân lao đã mua được fluoroquinolone ở tám nhà thuốc nhằm điều trị các triệu 
chứng rõ rệt của bệnh lao. Do fluoroquinolone là nhóm thuốc xương sống trong điều trị lao kháng 
thuốc, việc  bán và phân phối các thuốc này cần phải được lưu tâm hơn nữa.
Trong phần 2, chúng tôi tập trung vào phương pháp lấy mẫu và phân tích vệt máu khô (Dried Blood 
Spot, DBS) áp dụng cho các thuốc chống lao để từ đó có thể ứng dụng trong việc tối ưu hóa điều trị. 
Các nghiên cứu trước đây cho thấy sự biến thiên dược động học của các thuốc chống lao giữa các bệnh 




thuốc dưới ngưỡng điều trị trong khi có các bệnh nhân khác có thể chịu độc tính do nồng độ quá cao. 
Phân tích meta và mô hình dựa trên số liệu lâm sàng trong các nghiên cứu gần đây cho thấy sự biến 
thiên dược động học có liên quan đến việc thất bại trong điều trị cũng như làm phát sinh kháng thuốc. 
Do đó, cần thiết phải xây dựng một công cụ phục vụ cho thực hành giám sát nồng độ thuốc trong điều 
trị tại các nước đang phát triển, nơi tình hình dịch tễ lao là một vấn đề ngày càng lớn. 
Trong chương 4, một bài tổng quan đã được viết nhằm xác định các ưu khuyết điểm của phương pháp 
lấy mẫu và phân tích DBS. Chương này cũng thảo luận về cơ hội áp dụng phương pháp vệt máu khô 
trong điều trị lao tại các khu vực có nguồn lực hạn chế. Các vấn đề về kĩ thuật cũng như lâm sàng cần 
thiết cho việc phát triển phương pháp DBS cũng được tổng kết nhằm hỗ trợ xây dựng cũng như ứng 
dụng phương pháp này vào điều kiện thực tế lâm sàng.
Chương 5 mô tả việc xây dựng phương pháp định lượng moxifloxacin trong mẫu DBS. Moxifloxacin 
là một kháng sinh trong nhóm fluoroquinolone có hiệu lực với lao kháng thuốc và hiện đang được thử 
nghiệm lâm sàng pha 3. Phương pháp được xây dựng đảm bảo tính tuyến tính, tính chọn lọc, độ đúng 
và độ chính xác. Các yếu tố quan trọng có thể ảnh hưởng đến độ đúng độ chính xác của phương pháp 
như hematocrit, thể tích mẫu máu cũng được nghiên cứu. Thể tích mẫu máu không ảnh hưởng nhiều 
tới độ đúng và độ chính xác của phương pháp nên không cần phải sử dụng dụng cụ đo thể tích chính 
xác trong quá trình lấy mẫu. Hemtocrit có tương quan thuận với sai số hệ thống của phương pháp phân 
tích và do đó với các bệnh nhân có giá trị hematocrit quá cao hoặc quá thấp thì việc hiệu chỉnh có thể 
được cân nhắc.  Khả năng dàn trải khác nhau của máu trên mặt giấy do độ nhớt khác nhau có thể giải 
thích một phần ảnh hưởng của haematocrit đối với sai số hệ thống. Trong thẩm định lâm sàng, nồng 
độ thuốc trong mẫu DBS có tương quan tuyến tính khá chặt với nồng độ thuốc trong huyết tương 
(r2=0.966). Hệ số góc của đường hồi quy là 1.49 (khoảng tin cậy 95% 1.32-1.77) cho thấy rằng moxifloxa-
cin phân bố nhiều hơn trong tế bào máu so với huyết tương. Moxifloxacin cũng rất bền trong mẫu 
DBS. Không có sự phân hủy đáng kể nào tại điều kiện nhiệt độ thường sau ít nhất một tháng bảo quản.
Trong chương 6a và chương 6b, một phương pháp hiệu năng cao được xây dựng nhằm định lượng 
rifampicin, clarithromyicin và các chất chuyển hóa của chúng gồm 25-desacetyl rifampicin và 14 hydroxy 
clarithromycin trong mẫu DBS. Rifampicin là thuốc chống lao chủ lực với hoạt tính diệt khuẩn cao trên in 
vivo. Sự dao động cá thể về dược động học cũng như các tranh cãi hiện nay về liều tối ưu của thuốc này gợi 
ý rằng việc áp dụng TDM có thể có ích. Trước tiên, chúng tôi mô tả cách tiếp cận từng bước một nhằm loại 
bỏ hiệu ứng nhiễm chéo trong phương pháp được xây dựng và công bố trước đó. Việc thay cột sắc kí pha 
đảo C18 có gắn các nhóm phân cực bằng côt sắc kí pha đảo C18 thông thường đã loại bỏ được hiệu ứng 
này (chương 6a). Tiếp theo, chúng tôi áp kết quả này vào việc xây dựng phương pháp phân tích đối với 
mẫu phẩm DBS. Bằng việc pha thêm acid ethylenediaminetetraacetic (EDTA) và deferoxamin vào dung 
dịch chiết, “hiệu ứng matrix” do tương tác giữa rifampicin và các tạp chất nội sinh trong DBS được loại bỏ 
và hiệu năng xử lý mẫu được cải thiện. Kết quả trong thẩm định lâm sàng cho thấy mối tương quan cao 
giữa nồng độ trong DBS và huyết tương đối với rifampicin, clarithromycin và 14 hydroxy clarithromycin 
và gợi ý rằng kết quả phân tích từ DBS có thể được dùng để xác định nồng độ thuốc trong huyết tương. 
Thêm vào đó, các mẫu có nồng độ dưới ngưỡng định lượng cho kết quả giống nhau cho dù sử dụng DBS 
hay huyết tương. Do đó, việc lấy mẫu phân tích DBS có thể giúp xác định được các bệnh nhân không tuân 
thủ điều trị. Để đảm bảo sự tin cậy của kết quả lấy mẫu DBS ở các khu vực thiếu nguồn lực, độ ổn định của 
mẫu cần được đánh giá một cách toàn diện. Không giống như trong các mẫu dịch sinh học với độ ổn định 
thấp, rifampicin rất ổn định trong mẫu DBS (2 tháng ở nhiệt độ thường, 10 ngày ở 370C và 3 ngày ở 500C). 
Với kết quả đó, mẫu có thể được bảo quản và vận chuyển không cần các thiết bị làm lạnh (chương 6b).
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Trong chương 7, việc ứng dụng phương pháp lấy mẫu và phân tích DBS vào giám sát nồng độ thuốc 
trong điều trị được mô tả chi tiết với linezolid. Phương pháp DBS được xây dựng và thẩm định có tính 
lặp lại. Thẩm định trên lâm sàng được thực hiện bằng cách so sánh nồng độ DBS và huyết tương bằng 
hồi quy Passing-Bablok và phân tích Bland-Altman. Tỷ lệ nồng độ trong DBS so với huyết tương là 1.2 
(khoảng tin cậy 95% 1.12 – 1.27). Nồng độ thuốc trong DBS và plasma có độ tương hợp cao. Tương quan 
giữa chỉ số AUC0-24/MIC có mối tương quan cao giữa DBS và plasma (Spearman rho=0.976, n=8). Điều 
này cho thấy việc giám sát nồng độ thuốc dựa trên phương pháp DBS sẽ tương tự như dựa trên phân 
tích mẫu huyết tương. Hơn nữa, linezolid ổn định trong mẫu DBS sau 2 tháng bảo quản ở 370C và thậm 
chí ổn định ở nhiệt độ 500C trong một tuần. Kết quả này gợi ý rằng việc điều chỉnh liều dùng để hạn 
chế độc tính và đảm bảo nồng độ điều trị là khả thi ngay cả ở các khu vực thiếu nguồn lực bằng việc áp 
dụng phương pháp lấy mẫu DBS.
Trong chương 8, chúng tôi bàn luận về vai trò của các kết quả nói trên đối với việc kiểm soát bệnh lao 
tại các nước đang phát triển. Vai trò của nhà thuốc tư nhân trong chiến lược chống lao của chương trình 
chống lao quốc gia tại Việt Nam được xác định và tìm hiểu. Yêu cầu cá thể hóa trong điều trị lao tại các 
nước đang phát triển sử dụng phương pháp DBS được bàn luận. Chúng tôi đề xuất mô hình mang tính 
hệ thống trong việc thực hiện giám sát nồng độ thuốc nhằm hỗ trợ quyết định lâm sàng trong điều trị 
lao tại các khu vực thiếu nguồn lực dựa trên phương pháp lấy mẫu và phân tích DBS.
samenvaTTTinG neDerlanDs (DuTCh summary)
Wereldwijd is het streven het aantal doden door tuberculose (TB)  terug te dringen tot de helft van 
het aantal in de periode 1990-2015. Het uiteindelijke doel is in 2050 de ziekte mondiaal volledig uit te 
bannen. Dat is niet gemakkelijk, omdat door de HIV epidemie en de toenemende resistentie van TB 
verwekkers voor de beschikbare antimicrobiële middelen, behandeling van TB steeds lastiger wordt.
In Deel 1 van dit proefschrift wordt een veldstudie beschreven. Met behulp van  pseudopatiënten 
werd aan een groot aantal medewerkers van openbare apotheken in Hanoi (Vietnam) vragen gesteld. 
Deze waren bedoeld om de kennis in algemene zin te toetsen en ook om de adviezen te vergelijken, 
die waren gegeven aan  onze pseudopatiënten met symptomen die op TB leken. In hoofdstuk 2 
worden de details van dit onderzoek alsmede resultaten beschreven. Bijna de helft van de apotheek-
medewerkers herkende de TB patiënt niet voldoende, althans zag geen reden hem door te sturen 
voor verdere diagnose en behandeling  in een TB centrum. Een ander deel herkende de TB patiënt 
wel en stelde voor om bepaalde door de apotheek (zonder recept) te leveren antibiotica   al vast te 
gaan innemen. Slechts 11% van de pseudo-TB-patiënten werden daadwerkelijk direct doorverwezen 
naar een TB centrum.  De nationale TB-centra zijn gratis. In Vietnam kunnen apotheken een certificaat 
verwerven waarmee men aantoont dat men aan kwaliteitsprogramma’s meedoet.  Opmerkelijk was 
dat niet gecertificeerde apotheken de patiënt eerder naar een TB-centrum verwezen dan de gecertifi-
ceerde apotheken. In hoofdstuk 3 is gekeken naar de beschikbaarheid van antituberculose middelen 
in apotheken in Vietnam. Hierbij werden zowel geneesmiddelen uit de eerste lijn maar ook de reserve 
antibiotica beoordeeld. De meeste apotheken beschikken slechts over één of twee  antiTB middelen. 
Meestal is dit  isonizide en/of rifampicine.  Daarentegen beschikten de openbare apotheken dicht bij 
de gespecialiseerde tuberculoseklinieken over een groter assortiment anti TB middelen op voorraad. 
Een probleem  is dat antibiotica die ook voor andere dan TB-infecties gebruikt kunnen worden, zonder 
recept worden verstrekt. Met name het gebruik van rifampicine voor open wonden was opvallend: 31% 




keus middelen tegen  resistente vormen van TB. Toch werden de fluorochinolonen door 36% van de 
apothekers of –medewerkers  voor ‘andere’ infecties aanbevolen.
In Deel 2 van het proefschrift staat de toepassing van een nieuwe methode voor het in bloed  bepalen 
van verschillende antiTB-middelen centraal.  Deze zogenaamde droge bloedvlek methode (Dry Blood 
Spot- DBS)  stelt ons in staat geneesmiddelen te bepalen in slechts één druppel bloed, verkregen na 
een vingerprikje op filtreerpapier. De toepassing van deze DBS methode leent zich voor  het bepalen 
van bloedspiegels van antiTB-middelen. Hiermee kan de behandelend arts of ziekenhuisapotheker 
nagaan of therapeutisch spiegels worden bereikt,  de therapietrouw voldoende is en/of farmacoge-
netische variatie bij de bereikte bloedspiegel een rol speelt. Het voordeel van de DBS is dat men in 
niet stedelijke gebieden gemakkelijker bloed kan afnemen voor controle van de patiënten die anti-
TB middelen moeten gebruiken. In hoofdstuk 4 wordt een overzicht gegeven van de belangrijkste 
voor- en nadelen van de DBS methode. Bij de start van dit onderzoek werd de  methode voor anti-TB-
middelen nog niet, of op heel kleine schaal toegepast. Dit proefschrift geeft de aanzet tot uitgebreide 
toepassing van DBS bij patiënten met TB. In hoofdstuk 5 wordt de DBS methode voor  moxifloxacine 
beschreven, een middel dat inmiddels bij multiresistente TB in fase 3 trials wordt getest. De vereiste 
analytische DBS-methode ontwikkeling nam veel tijd in beslag, omdat er verschillende parameters 
die van invloed zijn op de reproduceerbaarheid van de methode, - onderzocht moesten worden. Zo is 
gekeken naar de invloed van de hoeveelheid rode bloedcellen (hematocriet) , het volume van de drup-
pel bloed   en de stabiliteit van de moxifloxacine in een DBS bij verschillende temperaturen en vochtig-
heidcondities. Het bleek dat moxifloxacine zich in de rode bloedcel ophoopt. De droge druppel bloed 
met moxifloxacine bleek tenminste 1 maand na afname nog bruikbaar voor analyse. In hoofdstuk 
6 en 7 is gekeken naar het ontwikkelen van  een methode voor de  bepaling van meerdere anti-TB-
middelen in één DBS. Rifampicine is een middel dat vrijwel door alle TB-patiënten wordt gebruikt. 
In de eerste opzet werd gekeken naar een combinatie rifampicine met clarithromycine en de respec-
tievelijke metabolieten 25-desacetylrifampicin en 14-hydroxychlarithromycine in DBS. Grote intra- en 
interindividuele variatie in farmacokinetiek van beide middelen rechtvaardigt het ontwikkelen van een 
DBS methodiek. Eerst in vitro en later ook voor in vivo monsters.  Door toevoegen van Na-edetaat als 
metaalcomplexvormer, lukte het om het matrix effect tussen rifampicine en endogene componenten 
in de DBS  te voorkomen. Hiermee kon een reproduceerbare methode voor rifampicine en clarithorm-
cyne en metabolieten  worden ontwikkeld. Rifampicine is in vloeibare media  (plasma/serum/bloed ) 
niet stabiel,  maar in de ‘droge’ DBS vorm wel.  In hoofdstuk 8 is een DBS methode ontwikkeld voor 
linezolid, een nieuw veelbelovend antibioticum dat bij TB inmiddels is toegepast . De analysemethode 
is goed reproduceerbaar en de stabiliteit van de DBS is tenminste 2 maanden bij 37 °C. In hoofdstuk 
9 worden de resultaten van het onderzoek op de toekomstige positie van openbare apotheken in het 
nationale TB programma in Vietnam besproken. Voorts wordt nader ingegaan op de mogelijke impact 
van onze resultaten op de verdere ontwikkelingen binnen de behandeling van TB. Inmiddels zijn er 
voldoende klinische monsters bestudeerd en vergeleken met een klassieke bepalingsmethode, om de 
toepassing van DBS als methode voor Therapeutic Drug Monitoring te rechtvaardigen.  
Toepassing van de DBS methode zal therapie op maat bij de tuberculosepatiënt mogelijk maken en daar-
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